[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 443
1. Manchana T, Khemapech N: Endometrial adenocarcinoma in young Thai women. Asian Pac J Cancer Prev; 2008 Apr-Jun;9(2):283-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma in young Thai women.
  • OBJECTIVE: To evaluate the clinicopathological characteristics and survival analysis in endometrial adenocarcinoma women younger than the age of 40 years compare to older women.
  • METHODS: Medical records of 423 endometrial adenocarcinoma patients who received primary surgical treatment at King Chulalongkorn Memorial Hospital during 1996-2005 were reviewed.
  • RESULTS: Up to 10% (42/423) of endometrial adenocarcinoma patients were younger than the age of 40 years.
  • No significant difference in surgical stage distribution and the other pathologic characteristics was demonstrated between both groups.
  • CONCLUSIONS: Obesity was the only independent factor associated with endometrial adenocarcinoma in young patients.
  • Distribution of the surgical stage and the other pathologic characteristics were similar between both groups without survival benefit in young patients.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712975.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


2. Caquant F, Mas-Calvet M, Turbelin C, Lesoin A, Lefebvre D, Narducci F, Querleu D, Leblanc E: [Endometrial cancer by laparoscopy and vaginal approach in the obese patient]. Bull Cancer; 2006 Apr;93(4):402-6
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial cancer by laparoscopy and vaginal approach in the obese patient].
  • To prove feasibility of laparoscopic and vaginal surgical approach in obese patients with endometrial cancer, 81 patients were included retrospectively in 2 Cancer Centres : 41 obese and 40 non obese.
  • Matching 41 obese patients treated by laparoscopy with 29 obese patients with endometrial cancer treated by laparotomy, hospital stay was shorter in the laparoscopic group (3.8 [2-8] vs 7.4 days [5-10] p < 0.001) and pelvic nodes (16.3 [3-50] vs 11.5 [2-34]), operative time (149.9 [80-300] vs 167.9 minutes [60-390]) and disease-free survival (93 vs 80 %) were similar.
  • For obese patients with stage I endometrial adenocarcinoma, laparoscopic approach should be first choice because of similar operative complications and pelvic nodes, shorter hospital stay and less abdominal wall morbidity associated with lower risk to delay adjuvant radiotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Gynecologic Surgical Procedures / methods. Laparoscopy / methods. Obesity / complications

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627243.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Colling R, Lopes T, Das N, Mathew J: Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma. BMJ Case Rep; 2010;2010
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma.
  • Metastasis to the uterine corpus is uncommon and secondary colorectal tumours of the endometrium are rare.
  • We describe a uterine tumour with components of both primary endometrial and metastatic colorectal carcinomata.
  • She had an abdominoperineal resection 3 years previously for a Dukes stage B rectal carcinoma.
  • A transvaginal ultrasonography showed a thickened endometrium.
  • Histology immunophenotyping showed a CK7+, CK20+, CA125- and CEA+ colorectal metastasis (a profile consistent with her previous cancer) associated with a primary CK7+, CK20-, CA125+ and CEA- endometroid endometrial adenocarcinoma.
  • We conclude this represents endometrial metastasis of colorectal carcinoma with coincident primary endometrial adenocarcinoma.
  • We speculate as to whether the endometrial carcinoma arose de novo or was induced by the colorectal metastasis, or whether the primary endometrial tumour provided a fertile site for the colorectal metastasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Carcinoma, Endometrioid / diagnosis. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / pathology. Endosonography. Female. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Imaging. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Apr;13(4):379-88 [10786803.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(2):122-6 [11446475.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):252-6 [15047246.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2163-9 [7127256.001]
  • [Cites] Jpn J Surg. 1991 May;21(3):352-6 [1857041.001]
  • [Cites] Pathologe. 1993 Jan;14(1):58-60 [8451231.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):383-6 [8804459.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):981-2 [10370650.001]
  • [Cites] Dis Esophagus. 2005;18(2):124-6 [16053489.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):101-20 [16633059.001]
  • [Cites] Surg Today. 2008;38(7):651-5 [18612793.001]
  • [Cites] APMIS. 2008 Jun;116(6):538-40 [18754330.001]
  • [Cites] Int J Surg Pathol. 2011 Dec;19(6):787-90 [19443868.001]
  • (PMID = 22791861.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3028565
  •  go-up   go-down


Advertisement
4. Lee CM, Szabo A, Shrieve DC, Macdonald OK, Tward JD, Skidmore TB, Gaffney DK: Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. Cancer; 2007 Nov 1;110(9):2092-100
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study.
  • BACKGROUND: Although endometrial cancer remains the most common gynecologic malignancy in the United States, differing approaches to adjuvant radiotherapy treatment for early disease exist within the medical community because of the lack of a national consensus.
  • METHODS: The authors studied patterns of adjuvant care for stage I and II endometrial adenocarcinoma using a large United States population database.
  • National Cancer Institute from 1988 to 2002, and 26,923 women with American Joint Committee on Cancer stage I and II endometrial adenocarcinoma were selected.
  • The following prognostic factors were analyzed: age, race, stage, grade, year of diagnosis, SEER registry location, and use and type of postoperative radiotherapy (RT).
  • RESULTS: Higher tumor grade and stage led to greater use of RT.
  • The odds ratio (OR) for adjuvant RT was 3.4 for stage IB versus stage IA and 51.8 for stage IC/II versus stage IA.
  • The effect of grade depended on stage: for stages IA and IB, the OR was 2.9 for grade 2 versus grade 1 and 11.7 for grade 3/4 versus grade 1; whereas, for stage IC/II, the OR was 1.5 for grade 2 versus grade 1 and 2.0 for grade 3/4 versus grade 1.
  • Within stage I, increasing substage and grade increased the odds of EBRT with or without BR compared with BR alone.
  • CONCLUSIONS: To the authors' knowledge, this was the largest patterns of care analysis to date of adjuvant RT in patients with stage I and II endometrial adenocarcinoma.
  • The current study revealed that there is significant diversity in the use of adjuvant RT across the United States, and the results reflected the absence of a national consensus on adjuvant treatment for early-stage disease.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Nomograms. Practice Patterns, Physicians' / statistics & numerical data. Radiotherapy, Adjuvant / utilization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17849468.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R30CA042014-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


5. Mhawech-Fauceglia P, Wang D, Kesterson J, Clark K, Monhollen L, Odunsi K, Lele S, Liu S: Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PLoS One; 2010;5(11):e15415
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma.
  • BACKGROUND: Endometrial cancer is the most common gynecologic malignancy in developed countries and little is known about the underlying mechanism of stage and disease outcomes.
  • The goal of this study was to identify differentially expressed genes (DEG) between late vs. early stage endometrioid adenocarcinoma (EAC) and uterine serous carcinoma (USC), as well as between disease outcomes in each of the two histological subtypes.
  • Remarkably, there was no overlap between the stage-derived DEGs and the prognosis-derived DEGs for each of the two histological subtypes.
  • CONCLUSION: This data, although preliminary, suggests that there might be involvement of distinct groups of genes in tumor progression (late vs. early stage) in each of the EAC and USC.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. Oligonucleotide Array Sequence Analysis / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1364-9 [20009891.001]
  • [Cites] Biochim Biophys Acta. 2009 Dec;1796(2):114-28 [19344752.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):6-11 [12517768.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5697-702 [14522886.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5988-95 [14676124.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):181-91 [15013523.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):292-300 [15099936.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1622-7 [1540970.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5100-3 [8221644.001]
  • [Cites] Cancer. 1994 May 1;73(9):2380-5 [7909491.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3371-6 [9042194.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3935-40 [9307275.001]
  • [Cites] J Soc Gynecol Investig. 1998 Sep-Oct;5(5):277-80 [9773404.001]
  • [Cites] Oncogene. 1998 Nov 26;17(21):2719-32 [9840936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8846-53 [15604243.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Bioessays. 2005 Jun;27(6):602-13 [15892119.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4056-66 [15930340.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] Trends Mol Med. 2005 Jul;11(7):336-40 [15961345.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4741-53 [15897902.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2553-61 [16510572.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1088-94 [16570270.001]
  • [Cites] BMC Cancer. 2006;6:144 [16737551.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):979-87 [17592263.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W169-75 [17576678.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):58-85 [17692468.001]
  • [Cites] Prostate. 2007 Dec 1;67(16):1770-80 [17929269.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):457-66 [18199540.001]
  • [Cites] Acta Pharmacol Sin. 2008 Mar;29(3):285-95 [18298893.001]
  • [Cites] Mol Biol Cell. 2008 Apr;19(4):1772-82 [18272789.001]
  • [Cites] PLoS Genet. 2008 Apr;4(4):e1000052 [18404217.001]
  • [Cites] Curr Issues Mol Biol. 2008;10(1-2):61-6 [18525107.001]
  • [Cites] Bioinformatics. 2008 Jul 1;24(13):1547-8 [18467348.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):768-73 [18682706.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):505-11 [18928665.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Br J Cancer. 2008 Dec 16;99(12):2083-7 [18985039.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2808-15 [18803288.001]
  • [Cites] Clin Exp Metastasis. 2009;26(2):143-51 [18979216.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jan;19(1):134-40 [19258955.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1095-102 [19277044.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Physiol Pharmacol. 2009 May;60 Suppl 1:57-63 [19609014.001]
  • [Cites] Semin Reprod Med. 2000;18(1):81-9 [11299523.001]
  • (PMID = 21079744.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE23518
  • [Grant] United States / NCI NIH HHS / CA / T32 CA108456
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2975707
  •  go-up   go-down


6. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY, To KF, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong YF: Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer; 2009 Mar 15;124(6):1358-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women.
  • The objective of this study, a parallel study to global gene expression profiling, was to identify dysregulated microRNAs (miRNAs) associated with endometrioid endometrial adenocarcinoma (EEC), examine their correlation with clinico-pathological characteristics and identify predicted target genes of the dysregulated miRNAs.
  • The expression of a sub-group of miRNAs was significantly correlated with clinico-pathological characteristics including stage, myometrial invasion, recurrence and lymph node involvement.
  • After transfection of a miR-205 inhibitor, the expression of miR-205 in endometrial cancer cell line RL95-2 cells decreased whereas its predicted target gene, JPH4, showed increased protein expression.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Endometrium / cytology. Endometrium / pathology. Female. Hong Kong. Humans. Middle Aged. Postmenopause. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065659.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Neoplasm
  •  go-up   go-down


7. Wu HM, Lai CH, Huang HY, Wang HS, Soong YK: A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer. Chang Gung Med J; 2008 Jan-Feb;31(1):102-6
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer.
  • Endometrial cancer is predominately a postmenopausal disease.
  • Endometrial cancer in women of childbearing age is relatively unusual.
  • Endometrial cancer is typically treated with hysterectomy.
  • After the development of endometrial cancer, successful pregnancy is rare.
  • We present a case of recurrent stage I endometrial adenocarcinoma in a 35-year-old woman.
  • Magnetic resonance imaging (MRI) revealed endometrial lesions without myometrium invasion and no pelvic lymph node enlargement.
  • On the basis of these observations and the low malignant potential of well-differentiated endometrial carcinoma, fertility-preserving treatment using Megace therapy was suggested.
  • Recurrent endometrial adenocarcinoma was documented using hysteroscopy and direct endometrial biopsy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Fertilization in Vitro. Megestrol Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Twins

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419059.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


8. Le Digabel JF, Gariel C, Catala L, Dhainaut C, Madelenat P, Descamps P: [Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey]. Gynecol Obstet Fertil; 2006 Jan;34(1):27-33
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey].
  • [Transliterated title] Hyperplasies atypiques et carcinomes de l'endomètre de stade I chez la femme jeune désirant une grossesse: le traitement conservateur est-il envisageable? Résultats d'une étude multicentrique française.
  • OBJECTIVES: To analyse the carcinological and obstetrical results of young women with atypical endometrial hyperplasia or endometrial adenocarcinoma, treated in a conservative way to allow pregnancy.
  • DISCUSSION AND CONCLUSION: Conservative treatment for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I can be considered in some cases to enable pregnancy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Hyperplasia / drug therapy. Endometrial Neoplasms / drug therapy. Infertility / etiology. Pregnancy Complications, Neoplastic / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406735.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


9. Puisoru M, Fatu C, Fatu IC: Histochemical evaluation of angiogenesis in endometrial adenocarcinoma. Ann Anat; 2006 May;188(3):255-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histochemical evaluation of angiogenesis in endometrial adenocarcinoma.
  • In this study, vascularization of tumor tissue was evaluated quantitatively in 36 cases of stage I endometrial adenocarcinoma.
  • The goal of this study was to evaluate whether the microvessel density correlates with the invasion potential of endometrial adenocarcinoma.
  • The results show an increase in the number of endothelial cells at different stages in endometrial adenocarcinoma stage I and a strong positive correlation between the endothelial-to-stromal ratio and tumor grading.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / pathology. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / pathology. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711164.001).
  • [ISSN] 0940-9602
  • [Journal-full-title] Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
  • [ISO-abbreviation] Ann. Anat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Lee CM, Szabo A, Shrieve DC, Macdonald OK, Gaffney DK: Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA; 2006 Jan 25;295(4):389-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma.
  • CONTEXT: The benefit of adjuvant radiation therapy (RT) in stage I endometrial adenocarcinoma remains controversial despite several phase 3 trials.
  • A total of 21,249 patients with American Joint Committee on Cancer stage IA-C node-negative endometrial adenocarcinoma comprised the study population.
  • MAIN OUTCOME MEASURES: Overall survival curves were constructed using Kaplan-Meier method and compared via stratified log-rank test within T stage/grade combinations, adjusted for age.
  • Relative survival was performed to assess the effects of age, race, stage, grade, whether nodes were examined, and whether adjuvant RT was administered.
  • Adjuvant RT significantly improved overall survival for patients with stage IC/grade 1 (P<.001) and stage IC/grades 3 and 4 (P<.001).
  • Cox proportional hazards regression analysis revealed a statistically detectable association of adjuvant RT with improved relative survival in patients with stage IC/grade 1 and stage IC/grades 3 and 4 (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.31-0.63; P<.001; and HR, 0.72; 95% CI, 0.57-0.92; P = .009; respectively).
  • CONCLUSIONS: As the largest reported population analysis to date of adjuvant RT in early stage endometrial adenocarcinoma, our study reveals a statistically significant association between improved overall and relative survival and adjuvant RT in stage IC disease (grades 1 and 3-4).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] JAMA. 2006 Jun 7;295(21):2482
  • (PMID = 16434629.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 2P30CA042014-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


11. Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA: A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecol Oncol; 2008 Jan;108(1):77-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma.
  • OBJECTIVES: Recent surveys have indicated that four alternatives are employed for adjuvant treatment of stage I endometrial adenocarcinoma: observation (OBS), high dose rate vaginal brachytherapy (VB), whole pelvic external beam radiotherapy (EBRT), or a combination of pelvic external beam with vaginal brachytherapy (COMB).
  • Our goal was to evaluate the cost-effectiveness of these alternatives for management of stage I endometrial adenocarcinoma.
  • CONCLUSION: Routine use of adjuvant EBRT or COMB in the management of surgical stage I endometrial adenocarcinoma is not cost-effective.
  • [MeSH-major] Adenocarcinoma / economics. Adenocarcinoma / radiotherapy. Decision Support Techniques. Endometrial Neoplasms / economics. Endometrial Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936341.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kalogiannidis I, Lambrechts S, Amant F, Neven P, VAN Limbergen E, Vergote I: Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: An analysis of 208 patients. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1885-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of lymphadenectomy and pelvic radiotherapy in patients with clinical FIGO stage I endometrial adenocarcinoma: An analysis of 208 patients.
  • Two hundred and eight patients with a clinical stage I endometrial carcinoma were studied (164 fulfilled the inclusion criteria).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Lymph Node Excision / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009987.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ibáñez Pinto A, Fernández Salgado E, Castro Ortiz E, Baltar Arias R, Vázquez Vázquez S, Ledo Barro L, Vázquez San Luis J, Vázquez Astray E: [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy]. Gastroenterol Hepatol; 2007 Nov;30(9):530-4
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy].
  • [Transliterated title] Hemorragia digestiva de origen incierto por un adenocarcinoma endometrial metastásico. Respuesta al tratamiento hormonal.
  • BACKGROUND: Endometrial cancer (EC) is the most common gynecologic malignancy.
  • CASE REPORT: We report the case of a 77-year-old woman who presented with intermittent gastrointestinal bleeding 2 years after treatment of stage IIb EC.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Gastrointestinal Hemorrhage / etiology. Medroxyprogesterone Acetate / therapeutic use. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / secondary. Retroperitoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980130.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  • [Number-of-references] 19
  •  go-up   go-down


14. Lavie O, Uriev L, Gdalevich M, Barak F, Peer G, Auslender R, Anteby E, Gemer O: The outcome of patients with stage I endometrial cancer involving the lower uterine segment. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1079-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of patients with stage I endometrial cancer involving the lower uterine segment.
  • The objective of this study was to evaluate whether lower uterine segment involvement (LUSI) correlates with recurrence and survival in women with stage I endometrial adenocarcinoma and whether it is associated with poor prognostic histopathologic features.
  • Three hundred seventy-five consecutive patients with endometrial carcinoma stage I compromised the study population.
  • The patients were divided into two groups according to the presence of LUSI with endometrial carcinoma.
  • LUSI was present in 89 (24%) patients with stage I endometrial carcinoma.
  • In patients with stage I endometrial cancer, the presence of LUSI is associated with grade 3 tumor, deep myometrial invasion, and the presence of CSLI.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081795.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Huh WK, Straughn JM Jr, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, Gold MA, McMeekin DS, Modesitt S, Cooper AL, Powell MA, Mutch DG, Nag S, Alvarez RD, Cohn DE: Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):886-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.
  • The objective of this study was to evaluate the treatment outcomes and risk factors of women with surgical stage I endometrial adenocarcinoma who were initially treated with surgery alone and subsequently developed isolated vaginal recurrences.
  • Patients with surgical stage I endometrial adenocarcinoma diagnosed from 1975 to 2002 were identified from tumor registry databases at seven institutions.
  • Sixty-nine women with surgical stage I endometrial cancer with isolated vaginal recurrences were identified.
  • Of the 69 patients, 10 (15%) were diagnosed with stage IA disease, 43 (62%) were diagnosed with stage IB disease, and 16 (23%) were diagnosed with stage IC disease.
  • The majority of isolated vaginal recurrences in women with surgical stage I endometrial cancer can be successfully salvaged with radiation therapy, further questioning the role of adjuvant therapy for patients with uterine-confined endometrial cancer at the time of initial diagnosis.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309665.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


16. Kalogiannidis I, Lambrechts S, Amant F, Neven P, Van Gorp T, Vergote I: Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. Am J Obstet Gynecol; 2007 Mar;196(3):248.e1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome.
  • OBJECTIVE: To determine the feasibility of laparoscopic-assisted vaginal hysterectomy (LAVH) in the treatment of clinical FIGO stage I endometrial adenocarcinoma and long-term survival outcome.
  • LAVH was associated with more surgical FIGO stage IA disease and a smaller tumor diameter.
  • CONCLUSION: LAVH with lymphadenectomy in selected population in high-risk patients with clinical stage I endometrial adenocarcinoma and with favorable body mass index of less than 35 kg/m2, appears to be safe procedure.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Hysterectomy, Vaginal / methods. Laparoscopy

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2008 Mar;198(3):347; author reply 347-8 [18177829.001]
  • (PMID = 17346541.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Atahan IL, Ozyar E, Yildiz F, Ozyigit G, Genc M, Ulger S, Usubutun A, Köse F, Yuce K, Ayhan A: Vaginal high dose rate brachytherapy alone in patients with intermediate- to high-risk stage I endometrial carcinoma after radical surgery. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1294-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal high dose rate brachytherapy alone in patients with intermediate- to high-risk stage I endometrial carcinoma after radical surgery.
  • The objective of this study was to analyze the efficacy and morbidity of vaginal cuff brachytherapy alone in intermediate- to high-risk stage I endometrial cancer patients after complete surgical staging.
  • Between October 1994 and November 2005, 128 patients with intermediate- to high-risk stage I endometrial adenocarcinoma were treated with high dose rate (HDR) brachytherapy alone after complete surgical staging.
  • The intermediate- to high-risk group was defined as any stage I with grade 3 histology or stage IB grade 2 or any stage IC disease.
  • Vaginal cuff brachytherapy alone is an adequate treatment modality in stage I endometrial adenocarcinoma patients with intermediate- to high-risk features after complete surgical staging with low complication rates.
  • [MeSH-major] Brachytherapy. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284452.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lord SR, Vasudev N, Knight S, Speirs V, Hall G: Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy.
  • : e16551 Background: The proportion of patients receiving chemotherapy for endometrial cancer is increasing both in the adjuvant and advanced setting.
  • The literature describes many prognostic immunohistochemical factors in early stage endometrial cancer, the majority of whom will not receive chemotherapy.
  • The aim of this study was to describe the biomarker expression for endometrial tumours treated with chemotherapy and to assess what constitutes a favourable and unfavourable profile for this patient group.
  • RESULTS: In total 199 patients received chemotherapy for endometrial cancer over the 12 year period studied.
  • The commonest histological subtypes were endometrioid adenocarcinoma (40%), serous carcinoma (24.1%) and mixed mullerian tumours (14.6%).
  • CONCLUSIONS: Positive staining for ERα and PR was of similar frequency to previous studies of early stage endometrial cancer and did not significantly influence prognosis.
  • A greater proportion of patients had serous morphology compared to published series of early stage endometrial cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.
  • RESULTS: 119 patients (stage I 92, II 11, III 15, and IV 1) were identified.
  • The OS for stage I and IIIC was 88% and 83%, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Salihoğlu Y, Keskin N, Topuz S, Küçücük S, Iyibozkurt C: Analysis of vaginal recurrences in stage I endometrial adenocarcinoma. Eur J Gynaecol Oncol; 2007;28(4):313-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of vaginal recurrences in stage I endometrial adenocarcinoma.
  • OBJECTIVE: To determine the risk of vaginal recurrence in Stage 1 endometrial cancer and treatment morbidity associated with different therapeutic approaches MATERIAL AND METHODS: Between 1995 and 2005, 341 patients with clinical Stage I endometrial cancer were treated at Istanbul Medical Faculty.
  • RESULTS: Overall 5-year survival rate for all patients with Stage I disease was 80%.
  • CONCLUSION: This selective treatment protocol for patients with Stage I endometrial cancer avoided radiation entirely in 38% of the patients while achieving a very low rate of vaginal recurrence and good overall survival.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Squamous Cell / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Vagina / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713101.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Rackow BW, Arici A: Endometrial cancer and fertility. Curr Opin Obstet Gynecol; 2006 Jun;18(3):245-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer and fertility.
  • PURPOSE OF REVIEW: Endometrial cancer can affect reproductive-age women who may desire fertility preservation.
  • This article discusses the current, available data about conservative management of endometrial cancer in young women.
  • RECENT FINDINGS: Reproductive-age women with well differentiated endometrial carcinoma have an overall favorable prognosis provided that the tumor is identified at an early, noninvasive stage; however, advanced disease can be present.
  • This article discusses current modalities to evaluate and clinically stage endometrial cancer including hysteroscopy, dilation and curettage, pelvic ultrasound, abdominopelvic computed tomography scan, pelvic magnetic resonance imaging, tumor marker CA125 level, and surgical exploration with laparoscopy or laparotomy.
  • Thorough evaluation is critical as 10 to 29% of young women with endometrial cancer have a synchronous ovarian malignancy.
  • Multiple effective protocols exist for conservative treatment of endometrial cancer, and the initial response rates are as high as 57 to 75%.
  • SUMMARY: There are no standard recommendations for selection of appropriate women, treatment protocols, or long-term surveillance for conservative management of clinical stage I endometrial adenocarcinoma, and larger prospective clinical studies are warranted.
  • [MeSH-major] Adenocarcinoma / complications. Endometrial Neoplasms / complications. Infertility, Female / prevention & control

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735822.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins
  • [Number-of-references] 65
  •  go-up   go-down


22. Peignaux K, Truc G, Blanchard N, Créhange G, Maingon P: [Stage I endometrial carcinoma]. Cancer Radiother; 2008 Nov;12(6-7):625-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stage I endometrial carcinoma].
  • [Transliterated title] Cancer de l'endomètre de stade I.
  • Most endometrial cancers are diagnosed at stage I (disease limited to the uterine corpus).
  • The definitive treatment for endometrial carcinoma consists in total abdominal hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy.
  • Postoperative radiotherapy plays a major role in the management of stage I endometrial cancer but the respective place of external radiotherapy and vaginal brachytherapy remains controversial.
  • Recent data suggest that vaginal brachytherapy is effective in preventing vaginal recurrence with lower toxicity and should be the treatment of choice for intermediate risk endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Combined Modality Therapy. Dose Fractionation. Female. Humans. Lymph Node Excision. Neoplasm Staging. Ovariectomy. Recurrence. Survival Analysis. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706845.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Demirol A, Bahce M, Ayhan A, Gurgan T: Pregnancy following intracytoplasmic sperm injection and preimplantation genetic diagnosis after the conservative management of endometrial cancer. Reprod Biomed Online; 2005 Jun;10(6):770-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy following intracytoplasmic sperm injection and preimplantation genetic diagnosis after the conservative management of endometrial cancer.
  • A rare case of a patient with conservatively treated endometrial carcinoma who conceived and delivered a healthy baby after the transfer of embryos with intracytoplasmic sperm injection (ICSI) and preimplantation genetic diagnosis (PGD) is presented.
  • A 41-year-old woman had an office hysteroscopy in the infertility work-up and stage I endometrial adenocarcinoma was diagnosed.
  • Repeated office hysteroscopy and endometrial sampling was performed after delivery.
  • The appearance of the endometrium was normal on hysteroscopy, and the histology report was normal.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Preimplantation Diagnosis. Sperm Injections, Intracytoplasmic

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. MEGESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970008.001).
  • [ISSN] 1472-6483
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EA6LD1M70M / Megestrol
  •  go-up   go-down


24. Monge AH, Pineda RP, del Rocio Estrada Hernandez M, Juárez EG, García JC: [Fallopian tube primary invasive adenocarcinoma associated with acute inflammatory pelvic disease. Case report and literature review]. Ginecol Obstet Mex; 2008 Feb;76(2):118-24
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fallopian tube primary invasive adenocarcinoma associated with acute inflammatory pelvic disease. Case report and literature review].
  • [Transliterated title] Adenocarcinoma invasor primario de trompa de falopio concomitante con enfermedad pélvica inflamatoria aguda. Comunicación de un caso y revisión de la bibliografía.
  • The primary fallopian tube invader adenocarcinoma is a preoperative diagnosis rarely reported in the literature, because is the most uncommon of all gynecological tumors, with prevalence from 0.3 to 1.8%.
  • In 25 to 60% of the cases a report of adenocarcinoma in the pap smear with negative endometrial biopsy can be found.
  • In some patients in early stage I or II with low risk, the complete staging could not be necessary.
  • The five years survival rate was 64% for stage I, 42% for stage II, 32% for stage III, and 17% for stage IV.
  • [MeSH-major] Adenocarcinoma / genetics. Fallopian Tube Neoplasms / complications. Pelvic Inflammatory Disease / complications

  • MedlinePlus Health Information. consumer health - Pelvic Inflammatory Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798405.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 3U02EL437C / Clindamycin; 75J73V1629 / Ceftriaxone
  • [Number-of-references] 10
  •  go-up   go-down


25. Siddiqui F, Ibrahim DR, Aref I, Lu M, Kim WS, Schultz D, Elshaikh MA: Clinical outcome of pathologic Stage IIA endometrial adenocarcinoma after intravaginal brachytherapy alone. Brachytherapy; 2009 Oct-Dec;8(4):396-400

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of pathologic Stage IIA endometrial adenocarcinoma after intravaginal brachytherapy alone.
  • PURPOSE: We studied the impact of different prognostic factors on the clinical outcome for the patients with pathologic Stage IIA endometrial adenocarcinoma who had surgical staging (SS) and received adjuvant high-dose-rate intravaginal brachytherapy (IVB) alone.
  • METHODS AND MATERIALS: Sixty-one patients with Stage IIA endometrial adenocarcinoma were retrospectively studied.
  • CONCLUSIONS: Our results suggest excellent local control with adjuvant IVB alone for selected patients with Stage IIA endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Endometrial Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19733127.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Giatromanolaki A, Bates GJ, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, Banham AH: The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol; 2008 Aug;110(2):216-21
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
  • In this study, we investigated the numbers of FOXP3(+) Tregs in the normal and malignat endometrium and examined potential links with tumor angiogenesis.
  • METHODS: Paraffin-embedded tissues from 79 patients with stage I endometrial adenocarcinoma and 12 samples from normal endometrium were analyzed using immunohistochemistry for the detection of FOXP3(+) lymphocytes.
  • RESULTS: In normal endometrium, FOXP3 was expressed by stroma infiltrating lymphocytes, with a mean number 8 (range 5-11) lymphocytes per x100 optical field.
  • CONCLUSIONS: The correlation between the presence of FOXP3(+) Tregs and high vessel density in endometrial adenocarcinomas suggests a link between immunity, intratumoral angiogenesis and poor prognosis.
  • However, further studies are required as significantly fewer Tregs were detected in the tumor microenvironment compared to normal endometrium.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / immunology. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / immunology. Forkhead Transcription Factors / immunology. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Endometrium / immunology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / immunology. Neovascularization, Pathologic / pathology. Receptors, Estrogen / biosynthesis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533240.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Receptors, Estrogen
  •  go-up   go-down


27. Qin Y, Peng Z, Gao Y: Bilateral femur metastasis in endometrial adenocarcinoma. Saudi Med J; 2008 May;29(5):766-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral femur metastasis in endometrial adenocarcinoma.
  • Bone metastasis of endometrial carcinoma is uncommon, and bilateral femur metastasis is extremely rare.
  • A 48-year-old woman with Federation International of Gynecology and Obstetrics stage IIB grade 2-3 endometrial adenocarcinoma underwent curative radical hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy followed by radiotherapy and chemotherapy.
  • Bone metastasis of endometrial carcinoma may occur at some unusual sites, and bilateral femur metastasis should be considered in patients.
  • Multimodal therapies are usually advocated for bone metastasis of endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Femoral Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454230.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Number-of-references] 10
  •  go-up   go-down


28. Zanagnolo V, Magrina JF: Robotic radical trachelectomy after supracervical hysterectomy for cut-through endometrial adenocarcinoma stage IIB: a case report. J Minim Invasive Gynecol; 2009 Sep-Oct;16(5):655-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic radical trachelectomy after supracervical hysterectomy for cut-through endometrial adenocarcinoma stage IIB: a case report.
  • We report on a patient with a cut-through endometrial malignancy after supracervical hysterectomy treated by radical trachelectomy and staging via a robotic approach.
  • A 58-year-old patient with incidental finding of a stage IIB G1 endometrial adenocarcinoma after a supracervical hysterectomy underwent robotic radical trachelectomy, bilateral pelvic lymphadenectomy, and ileal resection with anastomosis.
  • Robotic radical trachelectomy and pelvic lymphadenectomy appear to be feasible and safe for the treatment of endometrial malignancy discovered after supracervical hysterectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Cervix Uteri / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods. Robotics

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835816.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Labi FL, Evangelista S, Di Miscia A, Stentella P: FIGO Stage I endometrial carcinoma: evaluation of lung metastases and follow-up. Eur J Gynaecol Oncol; 2008;29(1):65-6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FIGO Stage I endometrial carcinoma: evaluation of lung metastases and follow-up.
  • PURPOSE: The aim of our study was to evaluate the incidence of lung metastases in the follow-up of women submitted to surgery for endometrial carcinoma, in particular for FIGO Stage I which is the lowest risk stage for this metastatic site.
  • METHODS: The study was conducted on 210 patients affected by FIGO Stage I endometrial cancer in the years 1990 to 2005 distributed as follows: 35 patients with Stage IA (limited to the endometrium), 150 patients with Stage IB (invasion up to and including half the myometrial thickness), 25 patients with Stage IC (invasion greater than half the myometrial thickness).
  • CONCLUSION: We are still following the cases and evaluating the biological behavior of this specific endometrial carcinoma and its reaction to further therapies.
  • We are also looking for possible clinical characteristics in disagreement with those reported in the literature, which would thus make it necessary to reconsider the prognosis and therapy of this stage of disease.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Lung Neoplasms / secondary. Sarcoma / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386467.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR: Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol; 2005 Nov;99(2):472-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
  • BACKGROUND: Conservative treatment with progestins is a reasonable treatment option for endometrial complex atypical hyperplasia and, in the experimental setting, for some women with grade 1 endometrial endometrioid adenocarcinoma.
  • The risk of progression to a high-stage endometrial cancer is quite low, with only two previously reported cases in the English literature.
  • CASE: A 40-year-old woman with endometrial complex atypical hyperplasia diagnosed by dilatation and curettage was managed conservatively with progestin therapy (initially, megesterol acetate; then, a combination oral contraceptive).
  • More than 2 years after her original diagnosis, she developed endometrial endometrioid adenocarcinoma, FIGO grade 2, with lymph node metastasis.
  • CONCLUSION: Currently, there are no good criteria for predicting which patients with complex atypical hyperplasia/grade 1 endometrioid adenocarcinoma will optimally respond to progestin therapy.
  • There is some evidence that endometrial complex hyperplasia demonstrating loss of MLH1 protein by immunohistochemistry is strongly related to subsequent or concurrent endometrial cancer, especially tumors of higher grade and stage.
  • In a woman with a biopsy diagnosis of endometrial hyperplasia, evaluation of MLH1 protein status by immunohistochemistry may provide useful information when medical management is being considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / drug therapy. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Progestins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099019.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


31. Cannon GM, Geye H, Terakedis BE, Kushner DM, Connor JP, Hartenbach EM, Bradley KA: Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma. Gynecol Oncol; 2009 May;113(2):176-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma.
  • PURPOSE: To evaluate locoregional control, disease free survival, and overall survival in patients treated with surgery and adjuvant radiation for stage II adenocarcinoma of the endometrium.
  • MATERIALS AND METHODS: All patients receiving adjuvant radiation at the University of Wisconsin following surgery for FIGO stage II adenocarcinoma of the endometrium between January 1991 and December 2006 were retrospectively reviewed.
  • RESULTS: Between January 1991 and December 2006, 71 patients with FIGO stage II adenocarcinoma of the endometrium (23 stage IIA, 48 stage IIB) received adjuvant radiation at the University of Wisconsin.
  • DISCUSSION: Local recurrence rates remain low after surgery and adjuvant radiation therapy for stage II endometrial cancer using a combination of VB and EXT tailored to the surgical and pathologic features.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217147.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, Yan Q: Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract; 2007;203(7):499-505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma.
  • To evaluate the association between the expression of human macrophage metalloelastase (matrix metalloproteinase-12, MMP-12) with cancer invasion and differentiation of endometrial adenocarcinoma, specimens from endometrial adenocarcinoma (n=61) of diverse stages and histologic types were collected from patients having undergone hysterectomy, and specimens from normal endometrium (n=38) were obtained from patients with benign diseases.
  • The positive rate of MMP-12 was significantly increased in endometrial adenocarcinoma (81.97%) as compared with that in normal endometrium (13.16%).
  • The results showed that expression of MMP-12 correlated with stage (p=0.022) and grade (p=0.018) of endometrial cancer.
  • MMP-12 immunoreactive proteins were found mainly on the glandular epithelial cells of endometrial adenocarcinoma.
  • The macrophage infiltration detected by CD68 immunohistochemical staining in endometrial adenocarcinoma was also higher than that in normal endometrium.
  • In this study, we show that in addition to macrophages, endometrial adenocarcinoma cells are able to express MMP-12.
  • Increased MMP-12 expression tended to be associated with the extent of adenocarcinoma invasion accompanied by marked macrophage infiltration.
  • Our results suggest that MMP-12 is an important oncogene in high-stage and high-grade endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Matrix Metalloproteinase 12 / biosynthesis. Neoplasm Invasiveness / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574772.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  •  go-up   go-down


33. Nofech-Mozes S, Ackerman I, Ghorab Z, Ismiil N, Thomas G, Covens A, Khalifa MA: Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol; 2008 Jun;129(6):912-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma.
  • To evaluate the value of lymphovascular invasion (LVI) in endometrial endometrioid adenocarcinoma (EEA) as a predictor for distant recurrence, we analyzed the histopathologic features of 513 consecutive cases of nonsurgically staged EEA limited to the uterus.
  • Studies to examine the role of adjuvant systemic therapy in patients with early-stage disease should be considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480008.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, Koukourakis MI, Tumour and Angiogenesis Research Group: Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol; 2006 Dec;103(3):912-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis.
  • In this study, the expression of LDH-5 was assessed in the normal and malignant endometrium.
  • EXPERIMENTAL DESIGN: Tissue specimens from 68 patients with clinical stage I endometrial adenocarcinoma of the endometrioid cell type and 20 samples from normally cycling endometrium were investigated immunohistochemically for the expression of LDH-5.
  • RESULTS: Unlike other normal epithelia, the glandular endometrial cells consistently expressed LDH-5 suggesting a role of this enzyme in the normal menstrual cycle.
  • Endometrial adenocarcinomas displayed LDH-5 expression in 31/68 (45.5%) cases with those having a high LDH-5 expression being connected with a low lymphocytic response; this may suggest an important role of LDH-5 and, presumably, lactate release in tumor escape from host immuno-surveillance.
  • CONCLUSIONS: LDH-5 expression is an independent prognostic marker in endometrial cancer, linked with impaired host immune response and activation of VEGFR2/KDR receptors in both cancer cells and tumor-associated vasculature.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. L-Lactate Dehydrogenase / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837029.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Vascular Endothelial Growth Factor A; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27.- / lactate dehydrogenase 5; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


35. Kato S, Espinoza N, Lange S, Villalón M, Cuello M, Owen GI: Characterization and phenotypic variation with passage number of cultured human endometrial adenocarcinoma cells. Tissue Cell; 2008 Apr;40(2):95-102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and phenotypic variation with passage number of cultured human endometrial adenocarcinoma cells.
  • Despite numerous endometrial cancer cell lines, little is know about the progression and transition of primary cultured endometrial tumours.
  • Herein, a stage I grade III endometrial adenocarcinoma was maintained in primary culture and the phenotypic and protein expression changes were observed in relation to passage number.
  • At early passage numbers, cultured human endometrial cancer (CHEC) cells displayed classic epithelial cell morphology, growing in groups in a glandular structure and staining positive for cytokeratin.
  • This report demonstrates that endometrial adenocarcinoma cells in culture can undergo phenotypic and protein expression changes reminiscent of epithelial-mesenchymal transition.
  • This work suggests that primary tumours and cell lines displaying stromal morphologies may have undergone epithelial-mesenchymal transition from an adenocarcinoma origin.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031781.001).
  • [ISSN] 0040-8166
  • [Journal-full-title] Tissue & cell
  • [ISO-abbreviation] Tissue Cell
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / GR071469
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins
  •  go-up   go-down


36. Gao M, Sun P, Wang J, Zhao D, Wei L: Expression of estrogen receptor-related receptor isoforms and clinical significance in endometrial adenocarcinoma. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):827-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of estrogen receptor-related receptor isoforms and clinical significance in endometrial adenocarcinoma.
  • The purpose of this study was to explore whether ERRs were involved in the tumorigenesis of endometrial adenocarcinoma.
  • We examined the expression of ERRs in endometrial adenocarcinoma and normal endometrium using semiquantitative reverse transcription-polymerase chain reaction and immunohistochemistry.
  • Clinicopathologic features including FIGO stage, histologic grade, myometrial invasion, and nodal metastasis were reviewed.
  • The expression rate and relative level of ERRalpha mRNA in ERalpha-positive endometrial adenocarcinomas were lower than in normal endometriums (P= 0.049 and P= 0.023), whereas the relative level of ERRgamma mRNA in ERalpha-positive endometrial adenocarcinomas was higher than in normal endometriums (P= 0.014).
  • Expression of ERRalpha mRNA was positively correlated with FIGO stage (P= 0.019) and myometrial invasion (P= 0.043).
  • Results suggested that ERRalpha and ERRgamma might participate in the tumorigenesis of endometrial adenocarcinoma.
  • ERRalpha and ERRgamma are promising to be new prognostic factors in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Estrogen / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681769.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / ERRalpha estrogen-related receptor; 0 / ESRRB protein, human; 0 / ESRRG protein, human; 0 / RNA, Messenger; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Estrogen
  •  go-up   go-down


37. Papanas N, Giatromanolaki A, Galazios G, Maltezos E, Sivridis E: Endometrial carcinoma and diabetes revisited. Eur J Gynaecol Oncol; 2006;27(5):505-8
MedlinePlus Health Information. consumer health - Diabetes Complications.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma and diabetes revisited.
  • OBJECTIVE: To investigate whether endometrial adenocarcinomas are intrinsically different in diabetic as compared to non-diabetic patients.
  • METHODS: A series of 208 patients with histologically confirmed endometrial adenocarcinomas were divided into groups of diabetic (n = 63) and non-diabetic (n = 145) patients.
  • The two groups were compared in terms of tumor morphology, FIGO stage, clinical risk factors and 12-year survival.
  • RESULTS: A history of a second neoplasia was significantly more frequent in diabetic than in non-diabetic patients (p = 0.001), but other endometrial cancer associated characteristics, such as tumor morphology, FIGO stage, obesity, hypertension, nulliparity, estrogen use and menopausal status did not differ between the groups.
  • CONCLUSIONS: A second neoplasia occurred significantly more frequently in diabetic than in non-diabetic patients with endometrial carcinoma, but long-term survival and other clinical and histological features were the same in the two groups.
  • These results indicate that endometrial adenocarcinoma is not intrinsically different in diabetic patients.
  • [MeSH-major] Adenocarcinoma / complications. Diabetes Complications. Endometrial Neoplasms / complications. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139988.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


38. Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S, Farias-Eisner R: Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol; 2010 Jan;202(1):73.e1-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.
  • OBJECTIVE: The objective of this study was to determine the efficacy of 3 previously described ovarian cancer serum biomarkers (apolipoprotein-1 [ApoA-I], prealbumin [TTR], transferrin [TF]) in the detection of endometrioid and papillary serous adenocarcinoma of the endometrium.
  • STUDY DESIGN: ApoA-I, TTR, and TF levels were measured in serum samples that were obtained from 433 individuals that included 90 women with normal endometrium, 210 women with early-stage endometrial cancer, and 133 women with late-stage endometrial cancer.
  • Multivariate regression models were constructed to evaluate the usefulness of the biomarkers in the detection of endometrial cancer.
  • RESULTS: ApoA-I, TTR, and TF distinguished normal samples from early-stage endometrial cancer with a sensitivity of 71% (specificity, 88%) and normal samples from late stage endometrial cancer with a sensitivity of 82% (specificity, 86%).
  • CONCLUSION: The biomarker panel that consists of ApoA-I, TTR, and TF may prove to be a useful clinical tool for the detection of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Apolipoprotein A-I / blood. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Endometrial Neoplasms / diagnosis. Prealbumin / analysis. Transferrin / analysis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adult. Female. Humans. Neoplasm Staging. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Mosby, Inc.
  • (PMID = 19766980.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Prealbumin; 0 / Transferrin
  •  go-up   go-down


39. Hidaka T, Nakamura T, Shima T, Yuki H, Saito S: Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. J Obstet Gynaecol Res; 2006 Jun;32(3):330-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
  • AIM: There is no standard chemotherapy regimen for patients with advanced endometrial adenocarcinoma.
  • METHODS: Twenty-eight patients who underwent surgery and had histologically confirmed advanced endometrial adenocarcinoma, International Federation of Gynecology and Obstetrics stage III/IV, received combination chemotherapy.
  • CONCLUSIONS: We conclude that paclitaxel/carboplatin is a promising regimen which could be substituted for CAP, with major activity and a highly acceptable toxicity profile for the treatment of advanced endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764625.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Kogan EA, Niziaeva NV, Demura TA, Ezhova LS, Unanian AL: [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma]. Arkh Patol; 2010 Jul-Aug;72(4):7-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma].
  • The purpose of the investigation was to study the morphological variants and molecular changes of the endothelial component of adenomyosis (AM) concurrent with endometrial adenocarcinoma (EAC).
  • The AM foci displayed the following types of epithelial changes: the epithelium corresponding to the proliferation stage; epithelial hyperplasia with and without atypia; atrophic epithelium.
  • [MeSH-major] Adenocarcinoma. Endometrial Neoplasms. Endometriosis. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis


41. Panggid K, Cheewakriangkrai C, Khunamornpong S, Siriaunkgul S: Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res; 2010 Oct;36(5):1044-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
  • AIM: To evaluate the clinicopathological factors associated with recurrence of disease in non-obese women with endometrial endometrioid adenocarcinoma.
  • METHODS: Medical records of the 138 patients who had newly diagnosed endometrial endometrioid adenocarcinoma with body mass index (BMI) <25 and underwent a complete staging surgery between 1999 and 2007 were reviewed.
  • LVSI was significantly correlated with lymph node metastasis (P < 0.0001), advanced FIGO stage (P < 0.0001), poor histological grade (P = 0.006), and deep uterine invasion (P < 0.0001).
  • The presence of LVSI, poor histological grade, and advanced stage were found significantly in patients who had disease recurrences (P = 0.026, P < 0.001, and P = 0.015, respectively).
  • Patients with LVSI, when stratified by FIGO stage, had a significant lower 5-year overall survival rate (58.8% versus 76.3%, log–rank test, P = 0.04).
  • CONCLUSION: LVSI, poor histological grade, and advanced stage were associated with disease recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21058438.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


42. Ben-Arie A, Tamir S, Dubnik S, Gemer O, Ben Shushan A, Dgani R, Peer G, Barnett-Griness O, Lavie O: Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer; 2008 Jul-Aug;18(4):813-9
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer?
  • The objective of the study was to compare the outcome measures of patients with endometrial adenocarcinoma diagnosed by endometrial biopsy, uterine curettage, or hysteroscopy.
  • Medical records of 392 women diagnosed with apparent early-stage endometrial adenocarcinoma were reviewed.
  • Data concerning the mode of diagnosis, histologic type and grade, surgical stage, peritoneal washings and lymph nodes status, and patient's outcome were retrieved.
  • During the study period, 99 (25.3%) cases were diagnosed by endometrial biopsy, 193 (49.2%) by uterine curettage, and 100 (25.5%) by hysteroscopy.
  • There were 347 (88.5%) cases of endometrioid adenocarcinoma and 45 (11.5%) of poor histologic types, including serous papillary, clear cell, and small cell cancer.
  • Three hundred and sixteen (80.6%) patients had stage I disease, 8 (2.0%) stage II, and 68 (17.4%) stage III.
  • Recurrent disease was found in 15.2% patients diagnosed by endometrial biopsy, in 4.7% where uterine curettage was used, and in 5% when hysteroscopy was applied.
  • No statistically significant difference in the survival rate between the different diagnostic methods applied was found, although a higher recurrence rate was noted following endometrial biopsy.
  • After a median follow-up time of 25 months for patients undergoing hysteroscopy, there was no difference in recurrence rates and/or overall survival compared to other diagnostic procedures implying that hysteroscopy can be safely used in the diagnosis of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / surgery. Hysteroscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961159.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


43. Fujiwara H, Saga Y, Takahashi K, Ohwada M, Enomoto A, Konno R, Tanaka A, Suzuki M: Omental metastases in clinical stage I endometrioid adenocarcinoma. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):165-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental metastases in clinical stage I endometrioid adenocarcinoma.
  • The clinical benefit of an omentectomy in endometrioid adenocarcinoma is unclear.
  • The objective of this study was to clarify the significance of an omentectomy performed for clinical stage I endometrioid adenocarcinoma.
  • A prospective study was performed on 134 patients with clinical stage I endometrioid adenocarcinoma who underwent omentectomy in addition to a staging laparotomy between 1998 and 2004: simple total hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph node dissection, and peritoneal cytology.
  • The omental metastases rate for clinical stage I endometrioid adenocarcinoma was lower than the positive rates for extrauterine spread to other sites; thus, the routine application of omentectomy as a part of a staging laparotomy may not be efficacious.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Omentum / pathology. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466052.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Li J, Kong WM: [Prognostic factors of stage III endometrial carcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Jan 20;89(3):198-200

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of stage III endometrial carcinoma].
  • OBJECTIVE: To investigate the prognostic factors of surgery-pathological stage III endometrial cancer.
  • METHOD: The clinical data of 102 patients with stage III endometrial cancer, aged 54.9 (27-79), 71 with endometrioid adenocarcinoma, 31 with non-endometrioid adenocarcinoma, 9 undergoing simple surgical treatment, and 42 receiving radiation, 16 receiving chemotherapy, and 35 receiving chemoradiation after surgery, were analyzed retrospectively.
  • RESULTS: Cox risk model analysis showed that the risk factors for the prognosis of stage III endometrial cancer were pathological types, method of treatment, vascular thrombosis, and age (all P < 0.05).
  • The average survival time of stage III a endometrial cancer patients purely positive in peritoneal cytology was 74.4 months, significantly longer than that of the patients with serosa and/or annex involvement (53.8 months, P < 0.05).
  • CONCLUSION: The independent prognostic factors of stage III endometrial cancer are pathological type, method of treatment, vascular thrombosis, and age.
  • The patients with, the prognosis of stage III a endometrial cancer simply positive in peritoneal cytology is better than that with serous and/or annex involvement.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537039.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


45. Solhjem MC, Petersen IA, Haddock MG: Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1379-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer.
  • PURPOSE: To determine the efficacy and complications of adjuvant vaginal high-dose-rate brachytherapy alone for patients with Stage I endometrial cancer in whom complete surgical staging had been performed.
  • METHODS AND MATERIALS: Between April 1998 and March 2004, 100 patients with Stage I endometrial cancer underwent surgical staging (total abdominal hysterectomy and bilateral salpingo-oophorectomy with pelvic +/- paraaortic nodal sampling) and postoperative vaginal high-dose-rate brachytherapy at our institution.
  • Most patients (73%) had endometrioid (or unspecified) adenocarcinoma, 16% had papillary serous carcinoma, and 11% had other histologic types.
  • The International Federation of Gynecology and Obstetrics stage and grade was Stage IA, grade III in 5; Stage IB, grade I, II, or III in 6, 27, or 20, respectively; and Stage IC, grade I, II, or III in 13, 17, or 10, respectively.
  • CONCLUSION: Adjuvant vaginal high-dose-rate brachytherapy alone may be a safe and effective alternative to pelvic external beam radiotherapy for surgical Stage I endometrial cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Cystadenocarcinoma, Papillary / radiotherapy. Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029796.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


46. Sultana N, Kiyani N: Histopathological features of endometrial carcinoma. J Coll Physicians Surg Pak; 2005 Sep;15(9):539-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological features of endometrial carcinoma.
  • OBJECTIVE: To evaluate and compare the histopathological features of endometrial carcinoma among women of various age groups.
  • PATIENTS AND METHODS: All cases of endometrial carcinoma who underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy were included.
  • Bleeding per vaginum was the commonest feature and endometrioid adenocarcinoma was the commonest histological type.
  • Amongst the 86 patients majority were well differentiated (grade-1) and stage-1, on FIGO staging.
  • Patients (<40 years) had endometrioid type of endometrial carcinoma, grade-1, and FIGO stage-1.
  • CONCLUSION: Patients with endometrial carcinoma presented in early stage (stage-1) and tumor well differentiated (grade-1).
  • In patients of more than 50 years of age even with stage-1, an increased frequency of deep myometrial invasion and less differentiated tumors, adnexal involvement, endocervical invasion, positive peritoneal cytology, vascular invasion and lymph nodes metastasis found.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181572.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


47. Dilek S, Dede M, Gezginç K, Yenen MC, Göktolga U, Ulutin HC, Deveci MS, Erdemoglu E, Aydogdu T: Does the localisation of tumour at stage I endometrial endometrioid adenocarcinoma have an impact on invasion of the tumour and individualisation of the surgical procedure? Eur J Gynaecol Oncol; 2008;29(2):138-40
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the localisation of tumour at stage I endometrial endometrioid adenocarcinoma have an impact on invasion of the tumour and individualisation of the surgical procedure?
  • MATERIAL METHOD: 106 clinically surgically stage I endometrial endometrioid carcinoma cases treated multi-institutionally at Gulhane Military Medical Academy (GATA) and Dr.
  • There was no statistically significant difference between only endometrial and only serous invasion rates.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods. Lymph Node Excision / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459547.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


48. Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A: Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol; 2005 Jun 1;23(16):3668-75
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
  • PURPOSE: Selective lymphadenectomy is widely accepted in the management of endometrial cancer.
  • Our goal was to assess effects of the extent of selective lymphadenectomy on outcomes in women with apparent stage I endometrial cancer at laparotomy.
  • PATIENTS AND METHODS: Patients with endometrial cancer who received primary surgical treatment between 1973 and 2002 were identified through an institutional tumor registry.
  • Inclusion criteria were clinical stage I/IIA disease and procedure including hysterectomy and selective lymphadenectomy (pelvic or pelvic + aortic).
  • CONCLUSION: These data add to the literature documenting the possible therapeutic benefit of selective lymphadenectomy in management of patients with apparent early-stage endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / surgery. Lymph Node Excision
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jun 1;23(16):3653-5 [15738544.001]
  • (PMID = 15738538.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Oshiro H, Miyagi Y, Kawaguchi Y, Rino Y, Arai H, Asai-Sato M, Nakayama H, Yamanaka S, Inayama Y, Fukushima N: Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm. Pathol Int; 2008 Jul;58(7):456-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm.
  • Reported herein is a case of endometrial adenocarcinoma without myometrial invasion that metastasized to the pancreas in a 69-year-old Japanese woman who had a history of hysterectomy.
  • Excised in distal pancreatectomy, the tumor was diagnosed as a pancreatic primary, an invasive papillary adenocarcinoma at first, but both the endometrial tumor and the pancreatic tumor demonstrated similar morphology and immunohistochemistry.
  • Furthermore, the identical nucleotide mutation of TP53 gene was observed from both the endometrial and pancreatic tumors.
  • The pancreatic tumor was therefore confirmed to be a metastasis from the primary endometrial adenocarcinoma.
  • Metastasis to the pancreas from endometrial carcinoma is extremely rare but must be considered even if the previous cancer was treated at an early stage.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Aged. Base Sequence. Diagnosis, Differential. Female. Genes, p53. Humans. Hysterectomy. Immunohistochemistry. Molecular Sequence Data. Mutation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577117.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


50. Eltabbakh GH, Shamonki J, Mount SL: Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors. Gynecol Oncol; 2005 Nov;99(2):309-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors.
  • OBJECTIVE: The purpose of our study was to assess the surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy showed well-differentiated (FIGO grade 1) carcinoma.
  • MATERIALS AND METHODS: A retrospective study was conducted including all women treated at the University of Vermont between 1992 and 2004 whose preoperative endometrial biopsy was reviewed by the staff at the Pathology Department and diagnosed as FIGO grade 1 adenocarcinoma and who received peritoneal washings, total abdominal (or laparoscopic) hysterectomy, bilateral salpingo-oophorectomy, and pelvic +/- para-aortic lymphadenectomy as part of their surgery.
  • CONCLUSIONS: Approximately 30% of women with endometrial carcinoma whose preoperative endometrial biopsy shows grade 1 tumors have grade 2 or 3 in the hysterectomy specimen and 12.6% have advanced surgical stage (stage III and IV) disease.
  • Women with preoperative endometrial biopsy showing grade 1 tumors who undergo surgical staging have excellent survival and acceptable operative morbidity.
  • [MeSH-major] Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cell Differentiation / physiology. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005945.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Akahira J, Tokunaga H, Toyoshima M, Takano T, Nagase S, Yoshinaga K, Tase T, Wada Y, Ito K, Niikura H, Yamada H, Sato A, Sasano H, Yaegashi N: Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology; 2006;71(5-6):333-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma.
  • AIMS: The aims of this study were to evaluate the factors affecting prognosis in patients with uterine sarcomas and to demonstrate that carcinosarcoma bears a similarity to high-grade endometrial carcinoma in terms of its prognosis and clinicopathological parameters.
  • Patient data of 921 cases of endometrial adenocarcinoma were also analyzed and compared to the data with the uterine sarcomas.
  • In carcinosarcoma, significant differences were observed with age (p = 0.0388), stage (p < 0.01) and surgical procedure (with or without pelvic lymphadenectomy, p = 0.0316).
  • In carcinosarcoma and G3 adenocarcinoma, no significant difference was identified with regard to overall survival in univariate (p = 0.191) and multivariate (p = 0.168) analyses.
  • CONCLUSION: Our results demonstrate that the clinical behavior of carcinosarcoma strongly resembles that of G3 endometrial adenocarcinoma, setting it apart from other 'pure' uterine sarcomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinosarcoma / diagnosis. Endometrial Neoplasms / diagnosis. Leiomyosarcoma / diagnosis. Sarcoma, Endometrial Stromal / diagnosis. Uterine Neoplasms / diagnosis


52. Havrilesky LJ, Secord AA, O'Malley DM, Broadwater G, Bae-Jump V, Cohn DE, Gehrig PA: Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. Gynecol Oncol; 2009 Aug;114(2):279-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.
  • OBJECTIVE: To determine factors related to recurrence and survival in women with stage IIIA endometrial cancer; to examine outcomes of women with IIIA1 disease.
  • METHODS: Multi-institutional analysis of women with stage IIIA endometrial carcinoma undergoing hysterectomy, bilateral salpingo-oophorectomy, lymphadenectomy, and pelvic cytology between 1980 and 2008.
  • RESULTS: 98 women underwent surgical staging for stage IIIA endometrial carcinoma.
  • CONCLUSIONS: Surgically assessed stage IIIA endometrial adenocarcinoma recurs in approximately 20-25% of cases.
  • A subset of stage IIIA1 with very low risk factors may be appropriate candidates for observation.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446319.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Izaki H, Takahashi M, Shiirevnyamba A, Taue R, Furumoto H, Bando Y, Murakami Y, Fukawa T, Koizumi T, Yamamoto Y, Yamaguchi K, Nakatsuji H, Kishimoto T, Fukumori T, Kanayama HO: Long-term recurrence-free survivor after laparoscopic removal of solitary adrenal metastasis from endometrial adenocarcinoma. J Med Invest; 2010 Feb;57(1-2):174-7
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term recurrence-free survivor after laparoscopic removal of solitary adrenal metastasis from endometrial adenocarcinoma.
  • Solitary adrenal metastasis from endometrial adenocarcinoma is extremely rare.
  • We report herein the case of a laparoscopically resected solitary adrenal metastasis originating from endometrial adenocarcinoma.
  • The patient was a 55-year-old woman who had undergone total abdominal hysterectomy for stage IIIc endometrial carcinoma, followed by 7 courses of adjuvant chemotherapy comprising carboplatin and paclitaxel.
  • To the best of our knowledge, this is the first case of solitary adrenal metastasis originating from endometrial adenocarcinoma that is controlled for the long term by successful laparoscopic resection.
  • [MeSH-major] Adenocarcinoma / pathology. Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Endometrial Neoplasms / pathology. Laparoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299759.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


54. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, Budczies J, Röske A, Dietel M, Denkert C: Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol; 2009 Jul;135(7):933-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
  • PURPOSE: Endometrial adenocarcinoma, due to a frequent activation of PI3 K/AKT has been proposed as a candidate neoplasm for the treatment with mTOR inhibitors.
  • Yet, data on the expression of mTOR cascade components in endometrial cancer are lacking.
  • METHODS: To provide a basis for futher studies with mTOR inhibitors, we used immunohistochemistry to evaluate the expression of activated mTOR pathway components in 57 endometrial cancer surgical specimens in vivo, and investigated in vitro the relation between the activation of AKT/mTOR and the response to rapamycin.
  • CONCLUSISONS: Expression of mTOR and 4EBP1 characterize high-grade, high-stage endometrial adenocarcinomas and might be predictive markers of a response to rapamycin.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Phosphoproteins / metabolism. Protein Kinases / metabolism. Sirolimus / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107520.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


55. Bidziński M, Dańska-Bidzińska A, Derlatka P, Sobiczewski P, Gmyrek L, Jońska-Gmyrek J, Panek G: [Recurrence risk analysis in patients treated for I clinical stage of endometrial cancer]. Ginekol Pol; 2007 Jun;78(6):471-5
MedlinePlus Health Information. consumer health - Women's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence risk analysis in patients treated for I clinical stage of endometrial cancer].
  • INTRODUCTION: The risk of endometrial cancer recurrence is estimated to be about 20%.
  • MATERIAL AND METHODS: Between the year 2001 and 2003, 203 from 243 patients with endometrial cancer underwent surgery.
  • CONCLUSION: In patients with endometrial cancer the risk of recurrences increases when lymph node metastases are recognized.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Women's Health
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adult. Cystadenocarcinoma, Papillary / secondary. Cystadenocarcinoma, Papillary / surgery. Female. Genital Neoplasms, Female / secondary. Genital Neoplasms, Female / surgery. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Poland. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899704.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


56. Srikantia N, B R, A G R, Kalyan SN: Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases. Indian J Med Paediatr Oncol; 2009 Apr;30(2):80-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases.
  • Endometrial adenocarcinoma is the third common malignancy of the female genital tract occurring most often in the postmenopausal age group.
  • High tumor grade, advanced surgical stage, and lymphovascular space invasion are implicated as poor prognostic factors for dissemination of disease.
  • We present an unusual case of endometrial adenocarcinoma in a premenopausal woman with simultaneous metastases in brain, liver, skin and skeletal system, within one month of completion of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):524-8 [15099973.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89 [15270671.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):333-9 [15297170.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Sep;35(9):1488-94 [18799902.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1715-20 [19443392.001]
  • (PMID = 20596308.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2885881
  • [Keywords] NOTNLM ; Adjuvant chemotherapy / endometrial carcinoma / multiple organ metastases
  •  go-up   go-down


57. Hanley KZ, Dustin SM, Stoler MH, Atkins KA: The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma. Int J Gynecol Pathol; 2010 Sep;29(5):445-51
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma.
  • Depth of myometrial invasion by endometrioid adenocarcinoma (EMAC) is one of the most important predictive factors of disease recurrence.
  • The purpose of this study was to evaluate the significance and frequency of the tumor involved AM in otherwise low-stage cancers.
  • The tumors were divided into 4 histologic groups: group 1, no involvement of AM by EMAC (n=38); group 2, tumor involved AM surrounded by endometrial stroma (n=31); group 3, tumor involved AM with incomplete peripheral endometrial stroma (n=10); and group 4, tumor involved AM with invasion into adjacent smooth muscle (n=3).
  • In otherwise low-stage tumors, our data support the concept that tumor involvement of the deeply located AM does not affect prognosis.
  • Myometrial-based foci of well-differentiated EMAC, completely or partially surrounded by endometrial stroma, most likely represents tumor colonized AM.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology

  • Genetic Alliance. consumer health - Adenomyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736770.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Yan X, Gao YN, Jiang GQ, Gao M, An N: [Impact of surgical resection extent on the prognosis of clinical stage I endometrial carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):208-12
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of surgical resection extent on the prognosis of clinical stage I endometrial carcinoma].
  • OBJECTIVE: To investigate the impact of surgical resection extent and other clinicopathological characteristics on the prognosis in patients with clinical stage I endometrial carcinoma.
  • METHODS: The data of 135 surgically treated patients with clinical stage I endometrial carcinoma were retrospectively analyzed.
  • The impact of surgery extent and other clinicopathological characteristics on the prognosis in patients with clinical stage I endometrial carcinoma were retrospectively analyzed.
  • RESULTS: There were no significant differences between two groups in the pathological stage, pathologic type, tumor grade, depth of myometrial invasion, vascular tumor emboli, ovary invasion, lymph node metastasis, positive peritoneal cytology and adjuvant therapy (P > 0.05).
  • Multivariate analysis demonstrated that the important risk factors for clinical stage I endometrial carcinoma were deep myometrium invasion, high pathological grade, positive peritoneal cytology and ovarian metastasis, rather than surgical resection extent.
  • CONCLUSION: Surgery extent is not an important factor affecting the prognosis in patients with clinical stage I endometrial carcinoma, and extended surgery does not improve their survival.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Clear Cell / therapy. Adult. Aged. Aged, 80 and over. Blood Loss, Surgical. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Adenosquamous / therapy. Chemotherapy, Adjuvant. Female. Humans. Length of Stay. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615262.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


59. Marchetti M, Vasile C, Chiarelli S: Endometrial cancer: asymptomatic endometrial findings. Characteristics of postmenopausal endometrial cancer. Eur J Gynaecol Oncol; 2005;26(5):479-84
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial cancer: asymptomatic endometrial findings. Characteristics of postmenopausal endometrial cancer.
  • Endometrial cancer affects patients at every age, however it occurs more frequently in menopause (> 50) and in postmenopause (> 70).
  • In some cases endometrial adenocarcinoma is asymptomatic and the diagnosis is casually made during ultrasound examination or by histological examination of a uterus surgically removed for other indications.
  • In these cases the most frequent findings are polyps and abnormally increased thickness of the endometrial mucosa.
  • In postmenopause polyps and abnormal endometrial thickness are usually limited to a small area and surrounded by atrophic mucosa.
  • Higher incidence rates of endometrial cancer were correlated with polyps and an increased number of serous type tumors were identified in the > 65-year age group.
  • Endometrial carcinoma may be estrogen correlated or non-estrogen associated.
  • Patients in postmenopause are often affected by non-estrogen correlated endometrial carcinoma.
  • According to Kurman and other authors the first type of endometrial adenocarcinoma (estrogen correlated) is characterized by low-grade malignancy.
  • In our case series including 102 women aged > 70 years with endometrial carcinoma we found that survival was correlated with stage and grading - early stages were the most frequent and the grade increased with stage.
  • [MeSH-major] Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285561.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 48
  •  go-up   go-down


60. Zaino RJ: FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol; 2009 Jan;28(1):1-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FIGO staging of endometrial adenocarcinoma: a critical review and proposal.
  • This paper selectively reviews some of the more problematic aspects of the current FIGO system, including the following: the distinction of tumors confined to the endometrium from those which are superficially myoinvasive; the method and utility of histologic grading of endometrial adenocarcinoma; the utility and reproducibility of the diagnosis of cervical epithelial and stromal invasion; the striking heterogeneity within and among stage III A, B, and C tumors and their differing prognostic significance.
  • It concludes with recommendations for changes in a future revision of the FIGO staging of endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Jan;29(1):63-6 [19952935.001]
  • [CommentIn] Int J Gynecol Pathol. 2009 Sep;28(5):477-8 [19696619.001]
  • (PMID = 19047915.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


61. Ju W, Park HM, Lee SN, Sung SH, Kim SC: Loss of hMLH1 expression is associated with less aggressive clinicopathological features in sporadic endometrioid endometrial adenocarcinoma. J Obstet Gynaecol Res; 2006 Oct;32(5):454-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of hMLH1 expression is associated with less aggressive clinicopathological features in sporadic endometrioid endometrial adenocarcinoma.
  • AIM: To assess the incidence and clinicopathological significance of microsatellite instability (MSI) and the protein expression of hMLH1 and hMSH2 in sporadic endometrioid endometrial adenocarcinoma (SEEA).
  • METHODS: A total of 50 patients with pure endometrioid sporadic endometrial adenocarcinoma were enrolled in the study.
  • No significant association was found between MSI status and clinicopathological parameters, including age, grade, stage, depth of myometrial invasion, lymph-vascular space invasion (LVI), lymph node involvement or peritoneal cytology.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Carrier Proteins / genetics. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Gene Expression. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984511.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


62. Cohn DE, Woeste EM, Cacchio S, Zanagnolo VL, Havrilesky LJ, Mariani A, Podratz KC, Huh WK, Whitworth JM, McMeekin DS, Powell MA, Boyd E, Phillips GS, Fowler JM: Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol; 2007 May;109(5):1062-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic correlates in surgical stage II endometrial carcinoma.
  • OBJECTIVE: To identify the surgical, pathologic, and therapeutic factors that influence outcome in patients with surgical stage II endometrial adenocarcinoma.
  • METHODS: All patients with comprehensively staged stage II endometrial adenocarcinoma were identified.
  • RESULTS: Of 162 patients with surgical stage II endometrial cancer, the median age was 65 years, and the median body mass index was 31.2 kg/m(2).
  • Stage IIA disease was present in 52% of cases, whereas stage IIB accounted for the remaining 48%.
  • CONCLUSION: In this large series of surgical stage II endometrial cancer cases, improved survival was noted relative to historical controls and in particular with radical compared with extrafascial hysterectomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470583.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. O'Brien DJ, Flannelly G, Mooney EE, Foley M: Lymphovascular space involvement in early stage well-differentiated endometrial cancer is associated with increased mortality. BJOG; 2009 Jun;116(7):991-4
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular space involvement in early stage well-differentiated endometrial cancer is associated with increased mortality.
  • OBJECTIVE: To study the relationship between lymphovascular space involvement (LVSI) in stage 1a or 1b well-differentiated endometrial cancer and survival.
  • DESIGN: Retrospective study consisting of a search of an oncology database to identify women with endometrial cancer between January 1990 and December 2004.
  • SAMPLE: Women who had well-differentiated stage 1a or 1b endometrial cancer.
  • METHODS: During the period 1990-2004, 226 patients with endometrial cancer were treated in the National Maternity Hospital, Dublin.
  • We looked at all patients who had well-differentiated endometrioid adenocarcinoma of the endometrium with invasion of <50% thickness of the myometrium.
  • MAIN OUTCOME MEASURES: Death from recurrence of endometrial cancer.
  • CONCLUSION: In patients with early stage well-differentiated adenocarcinoma of the endometrium, the presence of LVSI is associated with a high risk of death.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology. Lymphatic Vessels / pathology. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522800.001).
  • [ISSN] 1471-0528
  • [Journal-full-title] BJOG : an international journal of obstetrics and gynaecology
  • [ISO-abbreviation] BJOG
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens. J Med Assoc Thai; 2008 Sep;91(9):1313-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
  • OBJECTIVE: To evaluate the hysterectomy specimen findings in the patients who underwent fractional curettage (F&C) with presence of adenocarcinoma in both endocervical and endometrial specimens.
  • MATERIAL AND METHOD: Forty-one patients who had adenocarcinoma in both endocervical and endometrial specimens from F&C and underwent subsequent hysterectomy for surgical staging without pre-operative radiotherapy or chemotherapy at King Chulalongkorn Memorial Hospital between 1999 and 2007 were evaluated Histologic slides from both F&C and hysterectomy specimens were reviewed and assessed All cases of endometrial adenocarcinoma with cervical involvement (stage 2) in hysterectomy specimens were also assessed and compared to the results in F&C specimens.
  • RESULTS: Fifteen patients (36.6%) with both positive endocervical and endometrial specimens from F&C were diagnosed as endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Only 34.1% of cases were endometrial carcinomas with cervical involvement.
  • In the 35 cases with endometrial carcinoma stage 2, 60% had adenocarcinoma in both endocervical and endometrial specimens from F&C.
  • CONCLUSION: In the patients who had adenocarcinoma in both endocervical and endometrial specimens from fractional curettage, the most common final pathological diagnosis from hysterectomy specimens was endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Therefore, only 60% of endometrial carcinoma stage 2 revealed positive adenocarcinoma in both endocervical and endometrial specimens from fractional curettage.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Dilatation and Curettage. Endometrial Neoplasms / pathology. Endometrium / pathology. Hysterectomy

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843857.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


65. Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB: Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol; 2007 Nov;20(11):1156-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data.
  • We examined the expression profile of 12 immunomarkers in 200 endometrial carcinomas using a tissue microarray.
  • Correlation between clustering results and traditional prognosticators of endometrial carcinoma was examined by either Fisher's exact test or chi2-test.
  • The prognostic significance of the cluster groups was independent of tumor stage and patient age on multivariate analysis (P=0.014), but was not of independent significance when either tumor grade or cell type was added to the model.
  • The cluster group designation was strongly correlated with tumor grade, stage, and cell type (P<0.0001 for each).
  • Interlaboratory reproducibility of subclassification of endometrial adenocarcinoma by hierarchical clustering analysis was verified by showing highly reproducible assignment of individual cases to specific cluster groups when the immunostaining was performed, interpreted, and clustered in a second laboratory (kappa=0.79, concordance rate=89.6%).
  • Unsupervised hierarchical clustering of immunostaining data identifies prognostically relevant subsets of endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Endometrial Neoplasms / classification. Endometrial Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717550.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


66. Wang XY, Pan ZM, Chen XD, Lü WG, Xie X: Accuracy of tumor grade by preoperative curettage and associated clinicopathologic factors in clinical stage I endometriod adenocarcinoma. Chin Med J (Engl); 2009 Aug 20;122(16):1843-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of tumor grade by preoperative curettage and associated clinicopathologic factors in clinical stage I endometriod adenocarcinoma.
  • BACKGROUND: Preoperative tumor grading becomes one of the most important predictors for lymphadenectomy at primary surgery for clinical stage I endometriod adenocarcinoma.
  • This study aimed to evaluate the accuracy of tumor grade by preoperative curettage so as to achieve a better stratified management for clinical stage I endometriod adenocarcinoma.
  • METHODS: Clinical data of totally 687 patients with clinical stage I endometriod adenocarcinoma who underwent preoperative curettage and primary surgery were retrospectively collected.
  • Complete surgical staging seems to be necessary for clinical stage I endometriod adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Curettage / methods. Endometrial Neoplasms / diagnosis. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781357.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Wang XY, Pan ZM, Xie X: [Accuracy of preoperative tumor grading and intraoperative gross examination of myometrial invasion in clinical stage I endometriod adenocarcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):518-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Accuracy of preoperative tumor grading and intraoperative gross examination of myometrial invasion in clinical stage I endometriod adenocarcinoma].
  • OBJECTIVE: To evaluate accuracy of preoperative tumor grade and intraoperative gross examination of myometrial invasion in patients with clinical stage I endometriod adenocarcinoma for lymphadenectomy.
  • METHODS: Clinic-pathological data were retrospectively collected from 687 patients with clinical stage I endometriod adenocarcinoma who underwent operation in Women's Hospital, Zhejiang University School of Medicine from January 1999 to December 2008.
  • RESULTS: Sensitivity, specificity, accuracy, false negative rate, false positive rate, and positive and negative predictive value for the prediction of needing for intraoperative lymphadenectomy in patients with clinical stage I endometriod adenocarcinoma were 70.4%, 80.2%, 77.6%, 12.0%, 43.0%, 57.0% and 88.0%, respectively.
  • CONCLUSION: Prediction of needing for lymphadenectomy by preoperative tumor grade and intraoperative gross examination of myometrial invasion is reliable in clinical stage I endometriod adenocarcinoma patients, while there is a highly false negative rate in prediction of not needing for lymphadenectomy, while other prognostic factors such as patient age, tumor size, lymph node metastasis and extrauterine spread lesion should be together considered.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Curettage / methods. Endometrial Neoplasms / pathology. Myometrium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957552.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Barrier BF, Kendall BS, Sharpe-Timms KL, Kost ER: Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol; 2006 Oct;103(1):25-30
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma.
  • OBJECTIVES: The current study sought to determine if endometrial adenocarcinomas express human leukocyte antigen-G (HLA-G), an immune-regulatory protein, and if degree of expression correlates with the stage of carcinoma.
  • METHODS: Forty-four primary endometrial adenocarcinomas were tested using immunohistochemical staining with the 4H84 anti-HLA-G monoclonal antibody.
  • Results of staining were analyzed with respect to grade, tumor histology, and stage of disease.
  • Spearman rank correlation was used to assess tumor grade, histology, and disease stage as a function of HLA-G protein staining.
  • Receiver-operator characteristic (ROC) curve analysis was used to determine the feasibility of HLA-G protein staining as a clinical marker for advanced stage disease.
  • RESULTS: Immunohistochemical staining for HLA-G protein was seen in 55% (24/44) of primary site endometrial adenocarcinomas and localized to glandular but not stromal epithelium.
  • A significant correlation was seen with increasing HLA-G protein staining and increasing stage of endometrial cancer, P < 0.01.
  • CONCLUSIONS: HLA-G protein is expressed in a significant number of endometrial adenocarcinomas, in which it is localized to the glandular epithelium.
  • HLA-G may serve as a clinical marker for the preoperative prediction of metastatic endometrial cancer.
  • [MeSH-major] Adenocarcinoma / immunology. Endometrial Neoplasms / immunology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16530254.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


69. Wen HW, Tian F, Ma L, Liao QP: [Effects of postoperative chemotherapy on the prognosis of patients with high-risk early stage endometrial cancer]. Zhonghua Fu Chan Ke Za Zhi; 2009 Mar;44(3):196-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of postoperative chemotherapy on the prognosis of patients with high-risk early stage endometrial cancer].
  • OBJECTIVE: To investigate the effects of adjuvant chemotherapy for patients with high-risk stage I and II (early stage) endometrial cancer.
  • 2007, 106 cases with early stage high-risk endometrial cancer were treated in Peking University First Hospital and were divided into two groups based with postoperative adjuvant chemotherapy (ACT group, 66 cases) and without adjuvant chemotherapy (control group, 40 cases).
  • While, it were not significant difference in age, stage, histology, grade, radiotherapy alone, chemotherapy combined radiotherapy or progestin hormonal therapy (P>0.05).
  • On the multivariate analysis, adjuvant chemotherapy was found to affect independent prognostic covariates on early stage cases (P<0.05).
  • CONCLUSION: Postoperative adjuvant chemotherapy maybe improve the prognosis of patients with high-risk early stage endometrial cancer, which need to be further study by prospective randomized trials.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570445.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, Faught W, Dundas G: Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. Int J Gynecol Cancer; 2010 Nov;20(8):1356-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only.
  • OBJECTIVE: To examine the efficacy of vaginal vault radiotherapy as adjuvant treatment for patients with high-grade, stage I/II endometrial adenocarcinoma who have been surgically staged.
  • METHODS: A retrospective chart review of 77 women between 1995 and 2006 with high-grade surgically staged I and II endometrial adenocarcinoma, who were treated with postoperative vaginal vault radiotherapy alone, was performed.
  • Forty-two patients (55%) were classified as stage IB, having superficial myometrial invasion; 21 (27%) were stage IC, with deep invasion; and 6 (8%) were stage II, involving the cervix.
  • CONCLUSIONS: It seems that for this cohort of 77 patients with surgically staged I and II grade 3 endometrial adenocarcinoma, adjuvant vaginal vault radiotherapy alone leads to acceptable recurrence rates and survival while minimizing morbidity.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21051977.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Niazi TM, Souhami L, Portelance L, Bahoric B, Gilbert L, Stanimir G: Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1108-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma.
  • PURPOSE: Total-abdominal hysterectomy and bilateral salpingo-oophorectomy (TAHBSO) is the gold-standard therapy for patients with endometrial carcinoma.
  • METHODS AND MATERIALS: Between 1984 and 2003, 38 patients with Stage I and Stage II adenocarcinoma of the endometrium considered high operative risk received RT as the primary treatment.
  • Higher stage and higher grade were both associated with increased failure rate.
  • The 15-year disease-specific survival (DSS) was 78% for all stages, 90% for Stage I, and 42% for Stage II (p < 0.0001).
  • Patients with Stage I disease established by MRI (11 patients) and who received a total HDRB dose of 30 Gy had a DSS rate of 100% at 10 years.
  • CONCLUSION: Medically inoperable Stage I endometrial carcinoma may be safely and effectively treated with HDRB as the primary therapy.
  • In selected Stage I patients, our results are equivalent to that of surgery.
  • We believe that the alternative option of HDRB as the primary therapy for selected Stage I endometrial carcinoma, even in patients with low operative risks, needs further evaluation.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Endometrial Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099598.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Huang SY, Jung SM, Ng KK, Chang YC, Lai CH: Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol; 2005 May;97(2):652-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment.
  • BACKGROUND: There have been several reports about successful fertility-preserving treatment of endometrial carcinoma with subsequent pregnancy.
  • However, conservative hormonal treatment for early-stage endometrial cancer still entails some risk.
  • CASE: We present a 36-year-old nulliparous woman, initially diagnosed as clinical stage IA, grade 1 endometrial adenocarcinoma, receiving 6-month conservative treatment with remission achieved at 4 months from diagnosis.
  • Recurrence at the endometrium was documented at the end of treatment.
  • The final pathology revealed well-differentiated endometrioid adenocarcinoma with inner one-third myometrial invasion and right ovarian metastasis.
  • CONCLUSION: This case report signals a warning that negative preoperative imaging studies are not reassuring for a relapsing low-grade, early-stage endometrial carcinoma failing conservative treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Megestrol Acetate / therapeutic use. Ovarian Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863173.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


73. Patel S, Portelance L, Gilbert L, Tan L, Stanimir G, Duclos M, Souhami L: Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer. Int J Radiat Oncol Biol Phys; 2007 Aug 1;68(5):1438-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors and patterns of recurrence in patients with pathologic stage III endometrial cancer.
  • PURPOSE: To retrospectively assess prognostic factors and patterns of recurrence in patients with pathologic Stage III endometrial cancer.
  • METHODS AND MATERIALS: Between 1989 and 2003, 107 patients with pathologic International Federation of Gynecology and Obstetrics Stage III endometrial adenocarcinoma confined to the pelvis were treated at our institution.
  • CONCLUSIONS: Multiple prognostic factors predicting for the outcome of pathologic Stage III endometrial cancer patients were identified in this analysis.
  • [MeSH-major] Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418961.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Byrd LM, Swindell R, Webber-Rookes D, Hannon R, Hunter RD, Livsey J, Davidson SE: Endometrial adenocarcinoma: an analysis of treatment and outcome. Oncol Rep; 2008 Nov;20(5):1221-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma: an analysis of treatment and outcome.
  • This study aims to review the survival and morbidity in patients treated for endometrial cancer, at a single centre and analyses the effects of co-morbidity on these outcomes.
  • Case notes of all patients referred to the Christie Hospital with endometrial carcinoma from January 1, 1993 to December 31, 1995 (n=499) were reviewed.
  • Survival was significantly associated with FIGO stage, tumour grade, age (especially those >75 years) and co-morbidity (ACE-27 score).
  • These data demonstrate that survival in patients with endometrial carcinoma treated radically remains good, with the stage and grade of tumour being significant factors for overall survival.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / therapy. Endometrial Neoplasms / mortality. Endometrial Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949425.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


75. Schwab KV, O'Malley DM, Fowler JM, Copeland LJ, Cohn DE: Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma. Gynecol Oncol; 2009 Jan;112(1):146-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma.
  • OBJECTIVE: To determine if tumor-free distance (TFD) from the uterine serosa predicts surgicopathologic factors and outcome in surgically staged endometrial cancer, and to compare TFD with the traditional estimate of depth of myometrial invasion (DOI).
  • METHODS: Patients who underwent complete surgical staging for primary endometrial cancer at a single institution were identified from 2002-2005.
  • 77 patients were stage I, 11 were stage II, and 11 were stage III.
  • Univariate analysis demonstrated DOI to be a significant predictor of death, grade, lymph node metastasis, lymphovascular space involvement (LVSI), stage, lower uterine segment (LUS) involvement and adnexal involvement.
  • CONCLUSIONS: TFD, like DOI, is predictive of many surgicopathological variables and patient outcome in surgically staged endometrial cancer.
  • Although the performance characteristics may not be as powerful as DOI, the ease and reproducibility of this measurement may justify its inclusion in synoptic reporting of endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Myometrium / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937970.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Amato NA, Partipilo V, Mele F, Boscia F, De Marzo P: [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)]. Minerva Ginecol; 2009 Feb;61(1):1-12
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
  • [Transliterated title] Linfoadenectomia pelvica come alternativa alla radioterapia adiuvante nel carcinoma endometriale ad alto rischio di metastasi linfonodali in fase precoce (stadio I).
  • AIM: The aim of this study was to evaluate if the surgical approach without pelvic lymphadenectomy and with adjuvant radiotherapy in the patients suffering from endometrioid adenocarcinoma type at high risk (of lymphatic metastasis) in early stage can be substituted by only surgery with pelvic lymphadenectomy (with or without para-aortic lymphadenectomy).
  • The cancer grading (G) was defined before the surgery with an hystological exam on endometrial biopsies.
  • None of the patients at the stage IA had a relapse, but it occurred in the 8.7% of the cases (N.=2) IB and in the 10.5 % of the patients IC (N.=2).
  • [MeSH-major] Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Lymph Node Excision. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19204656.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


77. Ray K, Rocconi RP, Novak L, Straughn JM Jr: Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision. Gynecol Oncol; 2006 Nov;103(2):749-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision.
  • BACKGROUND: Endometrial cancer recurrences in surgical incisions are rare and thought to be due to seeding of the area with microscopic disease at the time of original surgery.
  • CASE: A 53-year-old woman underwent a dual procedure of a marsupialization of a benign bartholin's cyst with a hysteroscopic dilation and curettage for postmenopausal bleeding and received the diagnosis of endometrial adenocarcinoma.
  • Final pathology from subsequent hysterectomy and staging procedure demonstrated a surgical Stage IB Grade 1 endometrial cancer.
  • CONCLUSION: This case represents the only described endometrial cancer recurrence in a Bartholin's gland which was contaminated at the time of the original hysteroscopy and dilation and curettage.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Seeding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842845.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Kamoi S, Ohaki Y, Mori O, Kurose K, Fukunaga M, Takeshita T: Serial histologic observation of endometrial adenocarcinoma treated with high-dose progestin until complete disappearance of carcinomatous foci--review of more than 25 biopsies from five patients. Int J Gynecol Cancer; 2008 Nov-Dec;18(6):1305-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serial histologic observation of endometrial adenocarcinoma treated with high-dose progestin until complete disappearance of carcinomatous foci--review of more than 25 biopsies from five patients.
  • This study aimed to document chronologic histologic changes of endometrial biopsies from patients with endometrial adenocarcinoma on high-dose progestin therapy.
  • Seven patients with presumptive FIGO stage IA endometrial adenocarcinoma treated with medroxyprogesterone acetate 600 mg/day were investigated retrospectively.
  • Therefore, the morphologic change of the endometrial biopsy observed in earlier stage of treatment might be able to predict good response to high-dose progestin therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Estrogen Replacement Therapy. Progestins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18217978.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


79. Wethington SL, Barrena Medel NI, Wright JD, Herzog TJ: Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol; 2009 Oct;115(1):18-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery.
  • OBJECTIVE: Review the literature on positive peritoneal cytology in endometrioid endometrial adenocarcinoma, its prognostic value, proposed treatment strategies, and future avenues of investigation.
  • METHODS: PubMed search of articles pertaining to stage IIIA endometrioid endometrial adenocarcinoma identified over 50 articles that were reviewed.
  • Low-risk stage IIIA1 was defined as those with grade 1 or 2 disease, no evidence of cervical involvement, myometrial invasion less than 50% and no lymph vascular space invasion (LVSI).
  • In low-risk stage IIIA1 endometrial carcinoma patients, the rate of recurrence is 4.1%.
  • In contrast, in high-risk stage IIIA1 endometrial carcinoma patients the rate of recurrence is 32%, a statistically significant difference (p<0.001).
  • However, even in the low-risk cohort with stage IIIA1 some patients will recur.
  • Adjuvant therapy for low-risk stage IIIA diseased may or may not be of benefit.
  • A prospective, multicenter trial of comprehensively surgically staged patients with stage IIIA endometrial cancer is indicated in order to clearly define prognosis and treatment for these patients.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Peritoneal Cavity / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632708.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Croog VJ, Abu-Rustum NR, Barakat RR, Alektiar KM: Adjuvant radiation for early stage endometrial cancer with lymphovascular invasion. Gynecol Oncol; 2008 Oct;111(1):49-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiation for early stage endometrial cancer with lymphovascular invasion.
  • OBJECTIVE: To determine the impact of the decrease in use of postoperative pelvic external beam radiation (EBRT) in favor of intravaginal RT (IVRT) alone in patients with early stage endometrial cancer who had lymphovascular invasion (LVI).
  • METHODS: Between 11/1988 and 5/2005, 126 patients treated with simple hysterectomy and postoperative RT had a final pathologic diagnosis of stage IB-IIB adenocarcinoma of endometrioid histology with documented LVI.
  • [MeSH-major] Carcinoma, Endometrioid / radiotherapy. Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639922.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Metindir J, Dilek GB: The role of omentectomy during the surgical staging in patients with clinical stage I endometrioid adenocarcinoma. J Cancer Res Clin Oncol; 2008 Oct;134(10):1067-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of omentectomy during the surgical staging in patients with clinical stage I endometrioid adenocarcinoma.
  • OBJECTIVE: The aim of this study was to evaluate whether omentectomy should be a routine part of staging surgery in endometrioid adenocarcinoma.
  • METHODS: A retrospective study was performed on 65 patients who were primarily treated by total abdominal hysterectomy, salpingo-oophorectomy, bilateral pelvic and para-aortic lymphadenectomy, infracolic omentectomy and peritoneal cytology for clinical stage I endometrial carcinoma between January 2002 and December 2005.
  • Data on 65 patients who had been diagnosed with clinical stage I endometrial carcinoma were reviewed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386056.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Ballester M, Dubernard G, Rouzier R, Barranger E, Darai E: Use of the sentinel node procedure to stage endometrial cancer. Ann Surg Oncol; 2008 May;15(5):1523-9
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of the sentinel node procedure to stage endometrial cancer.
  • BACKGROUND: Lymph node status is a major prognostic factor and a criterion for adjuvant therapy in endometrial cancer.
  • The aims of this study were to determine the detection rate and the false-negative rate of the SN procedure, and its contribution to the staging of women with endometrial cancer.
  • METHODS: Forty-six patients with endometrial cancer underwent the sentinel node procedure followed by pelvic lymphadenectomy.
  • The stage predicted by magnetic resonance (MR) imaging correlated poorly with the Federation International of Gynaecology and Obstetrics (FIGO) stage.
  • CONCLUSION: The SN procedure can reliably determine lymph node status in women with endometrial cancer.
  • Given the limited capacity of MR imaging to detect myometrial invasion, and of biopsy to determine histological grade, our results support the systematic use of the SN procedure in women with endometrial cancer, including those with presumed early-stage disease and/or well-differentiated tumours.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / epidemiology. Cystadenocarcinoma, Serous / secondary. Cystadenocarcinoma, Serous / surgery. False Negative Reactions. Female. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jul;15(7):1815-7 [18473144.001]
  • (PMID = 18322758.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Hannuna KY, Putignani L, Silvestri E, Pisa R, Angioli R, Signore F: Incidental endometrial adenocarcinoma in early pregnancy: a case report and review of the literature. Int J Gynecol Cancer; 2009 Dec;19(9):1580-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental endometrial adenocarcinoma in early pregnancy: a case report and review of the literature.
  • Endometrial cancer is the most common neoplasia of the female reproductive system, with the highest incidence among uterine malignancies, and is rarely associated with pregnancy.
  • Thirty-five cases of pregnancy-associated endometrial cancer have been reported in literature, of which ours represents the 20th case diagnosed during the first trimester.
  • A 39-year-old woman, gravida 4, para 2, was diagnosed with a focal, well- to moderately differentiated endometrial adenocarcinoma (International Federation of Gynecology and Obstetrics stage IA and grades G1 and G2) after dilatation and curettage (D&C) for a spontaneous abortion.
  • Recurrence of endometrial cancer coexisting with early pregnancy has not been reported in the literature.
  • Conservative therapy for early endometrial cancer, diagnosed at the time of pregnancy, may be an option.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Cancer. 2010 Feb;20(2):313. Yael, Hannuna Karen [corrected to Hannuna, Karen Yael]; Lorenza, Putignani [corrected to Putignani, Lorenza]; Evelina, Silvestri [corrected to Silvestri, Evelina]; Roberto, Pisa [corrected to Pisa, Roberto]; Roberto, Angioli [corrected to Angioli, Roberto]; Fabrizio, Signore [corrected to Signore, Fabrizio]
  • (PMID = 19955941.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


84. Jolly S, Vargas C, Kumar T, Weiner S, Brabbins D, Chen P, Floyd W, Martinez AA: Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol; 2005 Jun;97(3):887-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer.
  • OBJECTIVE: Postoperative management of early stage adenocarcinoma of the endometrium remains controversial.
  • The use of pelvic radiation therapy as shown by the Gynecologic Oncology Group (GOG)-99 trial improves the event free interval at the cost of increased toxicity.
  • We reviewed and compared our results treating early stage endometrial adenocarcinoma using hypofractionated high dose rate (HDR) vaginal brachytherapy (VB) alone with the results of the GOG-99.
  • METHODS: From 1992 to 2002, 243 endometrial cancer patients were treated with TAH/BSO and selective lymph node dissection followed by adjuvant radiotherapy (RT).
  • Of these, 50 FIGO stage I-II (occult) adenocarcinoma (no clear cell or serous papillary) of the endometrium were managed with HDR hypofractionated VB as monotherapy using Iridium-192 to a dose of 30 Gy in 6 fractions twice weekly prescribed to a depth of 5 mm and median length of 4 cm.
  • RESULTS: Patient characteristics including age, stage, and grade were similar in our study and the GOG-99.
  • CONCLUSION: Stage I-II (occult) endometrial adenocarcinoma treated with postoperative HDR vaginal brachytherapy has similar overall survival, locoregional failure rates, and cumulative recurrence rates to standard fractionation external beam pelvic RT with the benefit of much lower toxicity rates and shorter overall treatment time.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943991.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Quddus MR, Sung CJ, Zhang C, Lawrence WD: Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci; 2010 Jul;17(7):673-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
  • Most endometrial carcinomas contain only 1 Müllerian cell type although the presence of 2 or more cell types within 1 tumor, for example a predominantly low-grade endometrioid carcinoma with a minor component (arbitrarily defined as 30% or less) of high-grade serous and/or clear cell carcinoma, is not uncommon.
  • The current study attempts to evaluate whether the presence of minor serous or clear cell components exerts an adverse effect on the prognosis in stage-I endometrial carcinomas of ''mixed-type.
  • '' The study cases include 22 cases of stage-I endometrioid carcinoma with a minor component of serous carcinoma and 14 cases of endometrioid carcinoma with a minor component of clear cell carcinoma.
  • The study cases were compared with 56 cases of histologically pure age-matched and stage-matched endometrioid carcinomas, 6 pure serous carcinomas, and 13 pure clear cell carcinomas.
  • Our study suggests that the presence of minor components of serous and clear cell carcinoma, defined as between 5% and 30%, within a mixed-type endometrial carcinoma appears to adversely influence the long-term survival of stage-I tumors, although a larger study is needed to corroborate our findings.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393071.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Burke C, Kelehan P, Wingfield M: Unsuspected endometrial pathology in the subfertile woman. Ir Med J; 2007 May;100(5):466-9
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unsuspected endometrial pathology in the subfertile woman.
  • Routine sampling of the endometrium is not considered necessary in the investigation of female infertility in the presence of normal menstruation.
  • We present the cases of five women diagnosed with endometrial pathology during the course of fertility investigations.
  • Three women had atypical polypoid adenomyoma, one had complex endometrial hyperplasia and one had stage 1 endometrial adenocarcinoma.
  • No woman had polycystic ovarian syndrome nor any other reason in her history to suspect endometrial pathology.
  • With current trends of increasing obesity and later age at attempted conception, the possibility of discovering endometrial pathology during fertility investigation is likely to increase.
  • We believe that a thorough menstrual history and careful assessment of the endometrium is warranted in all women with fertility problems.
  • If this ultrasound examination and the woman's menstrual history are both normal, no further evaluation of the endometrial cavity is routinely required.
  • This is ideally performed via hysteroscopy with endometrial sampling or excision of focally abnormal areas.
  • [MeSH-major] Endometrium / pathology. Fertility. Infertility, Female. Uterine Diseases / pathology. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Female Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727123.001).
  • [ISSN] 0332-3102
  • [Journal-full-title] Irish medical journal
  • [ISO-abbreviation] Ir Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


87. Dilek S, Dilek U, Dede M, Deveci MS, Yenen MC: The role of omentectomy and appendectomy during the surgical staging of clinical stage I endometrial cancer. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):795-8
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of omentectomy and appendectomy during the surgical staging of clinical stage I endometrial cancer.
  • Assessment of extrauterine spread is the most important objective of surgical staging in the endometrioid adenocarcinoma of uterine corpus.
  • In this study, our objective was to determine whether omentectomy and appendectomy should be a part of the surgical staging in endometrioid adenocarcinoma of uterine corpus.
  • Fifty-one patients who were diagnosed as clinical stage I endometrioid adenocarcinoma of corpus uteri were reviewed.
  • [MeSH-major] Adenocarcinoma / pathology. Appendectomy. Endometrial Neoplasms / pathology. Omentum / surgery. Peritoneal Cavity / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681763.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Chura JC, Brooker D, Downs LS Jr: Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature. Gynecol Oncol; 2006 Oct;103(1):336-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature.
  • We report a case of an adenocarcinoma arising in a defunctionalized bladder that presented as locally advanced endometrial carcinoma.
  • CONCLUSION: Carcinoma developing in the bladder after urinary diversion presents at an advanced stage and has associated poor overall survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793125.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Obermair A, Cheuk R, Pak SC, Perrin L, Nicklin J, Crandon A, Land R, Chennakes SK, Janda M, Tripcony L: Disease-free survival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma. Gynecol Oncol; 2008 Sep;110(3):280-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-free survival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma.
  • PURPOSE: To compare the disease-free survival (DFS) of patients with surgical stage 1, intermediate-risk endometrial adenocarcinoma (EAC) treated with primary surgery with or without adjuvant vaginal vault brachytherapy (VVBT).
  • PATIENTS AND METHODS: A retrospective chart review identified 575 patients with stage 1B, 1C or 2A endometrial cancer who had surgery between 1990 and 2004.
  • Multivariate analysis demonstrated that increasing patient's age at diagnosis and stage 1C or 2A disease were independent risk factors for recurrence whereas the grade of differentiation and the type of treatment (surgery alone vs. surgery followed by postoperative VVBT) were not associated with a change in DFS.
  • CONCLUSION: Postoperative VVBT was not associated with a measurable reduction in the risk of recurrence in surgical stage 1, intermediate-risk endometrial cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Endometrial Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777645.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Crosby MA, Tward JD, Szabo A, Lee CM, Gaffney DK: Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma? Am J Clin Oncol; 2010 Aug;33(4):364-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma?
  • INTRODUCTION: The benefit of adjuvant external beam radiation therapy (EBRT) in combination with intravaginal brachytherapy (BT) in stage I and II endometrial adenocarcinoma remains controversial.
  • A total of 3395 patients with stages IB, IC, and II node-negative endometrial adenocarcinoma comprised the population.
  • Overall survival (OS) and relative survival (RS) curves were constructed via the Kaplan-Meier method and subgroups were compared via stratified log-rank test within T stage/grade combinations.
  • CONCLUSIONS: This large population-based study revealed no improvement in OS or RS with the addition of BT to EBRT in high risk stage I and stage II endometrial cancer.
  • [MeSH-major] Brachytherapy / methods. Endometrial Neoplasms / radiotherapy. Radiotherapy / methods. Uterine Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20689365.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Xie R, Loose DS, Shipley GL, Xie S, Bassett RL Jr, Broaddus RR: Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Mod Pathol; 2007 Oct;20(10):1045-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypomethylation-induced expression of S100A4 in endometrial carcinoma.
  • We hypothesized that S100A4 would be overexpressed in endometrial carcinoma compared to benign endometrium.
  • Quantitative real-time RT-PCR (qRT-PCR) was used to quantify the mRNA level of S100A4 in benign endometrium (n=19), endometrioid adenocarcinoma (n=87), and non-endometrioid tumors (n=21).
  • Expression in grade 1 and grade 2 endometrioid tumors was comparable to that of normal endometrium, which was quite low.
  • Expression was significantly higher in stage III and IV tumors compared with stage I.
  • By immunohistochemistry, S100A4 was expressed in the tumor cell cytoplasm of poorly differentiated tumors, but was not detected in normal endometrial glandular epithelium.
  • In benign endometrium, S100A4 expression was confined to stromal cells.
  • However, methylation of the S100A4 gene was detected in benign endometrium and grade 1 tumors with low S100A4 expression.
  • These methylation results were verified in endometrial cancer cell lines with differential baseline levels of S100A4 protein.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic. S100 Proteins / genetics
  • [MeSH-minor] Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrium / metabolism. Female. Gene Expression. Humans. Immunoenzyme Techniques. Mixed Tumor, Mullerian / genetics. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / pathology. Neoplasm Staging. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673926.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


92. Ren YL, Wang HY, Shi DR, Yang WT, Sun Z, Chen Y: [Combined treatment and prognostic factors for stage III and IV endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2008 Jul;43(7):523-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined treatment and prognostic factors for stage III and IV endometrial carcinoma].
  • OBJECTIVE: To evaluate prognostic factors and treatment of patients with advanced stage endometrial cancer.
  • METHODS: One hundred and eighteen patients with advanced stage endometrial cancer were treated in our hospital between January 1996 and December 2006.
  • The 3-year overall survival for patients with stage III and stage IV was 78.3% and 39.4%, and for endometrioid and nonendometrioid endometrial carcinoma was 69.3% and 42.0%, respectively.
  • Patients with late stages, deep myometrial invasion, nonendometrioid endometrial cancer, poor differentiation, without lymphadenectomy and without radiochemotherapy after surgery were associated with a worse prognosis by univariate analysis (P < 0.05), while in a multivariate analysis only late stages and deep myometrial invasion were associated with a poor prognosis (P < 0.05).
  • CONCLUSIONS: Pathological stage and myometrial invasion are independent prognostic factors for late stage endometrial cancer.
  • Satisfactory cytoreduction surgery and lymphadenectomy, followed by postoperative radiochemotherapy, except for stage IIIa patients with positive cytology only, are recommended in order to improve prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080517.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


93. Watanabe J, Watanabe K, Jobo T, Kamata Y, Kawaguchi M, Imai M, Okayasu I, Kuramoto H: Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:452-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.
  • We reported that p27 induced by medroxyprogesterone acetate (MPA) may be involved in the progestin-induced growth suppression of human endometrial adenocarcinoma cells.
  • The clinical responses of 15 patients with endometrial carcinoma treated with MPA were examined. p27 expression was evaluated by immunohistochemical staining.
  • The former was significantly higher than the latter. p27 expression could predict the effectiveness of MPA treatment for endometrial carcinoma at an early stage of the 4-month period in MPA therapy and could be a useful predicting marker for MPA.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Proliferating Cell Nuclear Antigen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515645.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


94. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Crocè C, Mangioni C: Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst; 2008 Dec 3;100(23):1707-16
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
  • BACKGROUND: Pelvic lymph nodes are the most common site of extrauterine tumor spread in early-stage endometrial cancer, but the clinical impact of lymphadenectomy has not been addressed in randomized studies.
  • We conducted a randomized clinical trial to determine whether the addition of pelvic systematic lymphadenectomy to standard hysterectomy with bilateral salpingo-oophorectomy improves overall and disease-free survival.
  • METHODS: From October 1, 1996, through March 31, 2006, 514 eligible patients with preoperative International Federation of Gynecology and Obstetrics stage I endometrial carcinoma were randomly assigned to undergo pelvic systematic lymphadenectomy (n = 264) or no lymphadenectomy (n = 250).
  • [MeSH-major] Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology. Hysterectomy. Lymph Node Excision. Ovariectomy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / pathology. Aged. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Mixed Tumor, Mullerian / mortality. Mixed Tumor, Mullerian / pathology. Neoplasm Staging. Patient Selection. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant. Research Design

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2009 Jun 16;101(12):897-8; author reply 898-9 [19509367.001]
  • [CommentIn] J Natl Cancer Inst. 2008 Dec 3;100(23):1660-1 [19033560.001]
  • (PMID = 19033573.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00482300
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Kumar VJ, Nin CY, Kuei LY, Tan KH, Yeo R, Lam PY: Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer; 2010 May;20(4):564-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.
  • INTRODUCTION: Advanced age, deep myoinvasion, whole cavity or lower uterine segment tumors, poor differentiation, and lymphovascular space invasion are known to increase recurrence risk and adversely affect survival in stage I endometrioid adenocarcinoma of the uterus.
  • METHODS: Data of 162 patients with surgical stage I endometrioid adenocarcinoma of the uterus with an increased risk of recurrence were reviewed from the year 1997 to 2008 at KK Gynaecological Cancer Centre, Singapore.
  • Most patients (54.3%) had surgical stage IC endometrioid adenocarcinoma, whereas the rest had stage IB.
  • Stage IC had 77.78% recurrences, whereas stage IB had 22.22%, the median time being 19 months.
  • There was no recurrence in grade 3 tumors, with a 100% 5-year survival rate for stage IC grade 3.
  • Age, lymphovascular space invasion, and tumor volume and location were not significant parameters in surgical stage I endometrioid adenocarcinoma patients who failed.
  • The median survival for recurrent endometrial cancer was 5 years.
  • [MeSH-major] Brachytherapy. Carcinoma, Endometrioid / mortality. Endometrial Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality. Uterine Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686374.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Barney BM, MacDonald OK, Lee CM, Rankin J, Gaffney DK: An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer. Brachytherapy; 2007 Jul-Sep;6(3):201-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer.
  • Our primary endpoint was to assess the significance of simulation in women who received adjuvant intracavitary high-dose-rate brachytherapy (HDR-BT) for early-stage endometrial adenocarcinoma.
  • METHODS AND MATERIALS: Twenty-four consecutive women with early-stage endometrial cancer treated with adjuvant HDR-BT were evaluated.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Endometrial Neoplasms / radiotherapy. Postoperative Care / methods. Radiotherapy Planning, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681241.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Sebastianelli A, Renaud MC, Grégoire J, Roy M, Plante M: Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease. J Obstet Gynaecol Can; 2010 Sep;32(9):856-60
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease.
  • OBJECTIVE: To evaluate if a preoperative serum CA 125 level>or=35 kU/L in patients with endometrial cancer correlates with a surgical stage III or IV and poor histopathological prognostic factors.
  • METHODS: We conducted a retrospective cohort study of 254 patients who underwent hysterectomy and full staging for endometrial cancer.
  • RESULTS: A total of 186 (73%) patients had stage I or II disease and 68 (27%) had stage III or IV disease.
  • A statistically higher number of patients from the stage III or IV group had a serum CA 125 level>or=35 kU/L (58%) compared with the stage I or II group (16%) (OR 7.44; P<0.001).
  • Patients with stage I or II disease and serum CA 125>or=35 kU/L (46%) had significantly more frequent deep myometrial invasion (>50%) than did those with serum CA 125<35 kU/L (18%) (OR 3.68; P=0.006).
  • CONCLUSION: Assay of the preoperative serum CA 125 level is a very simple test to detect patients with more advanced stage endometrial adenocarcinoma.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoma / blood. Carcinoma / pathology. Endometrial Neoplasms / blood. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21050518.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


98. Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S: Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer; 2009 Feb;19(2):249-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients.
  • BACKGROUND: There are therapeutic dilemmas regarding fertility-preserving treatment among young women with well-differentiated endometrial carcinoma.
  • MATERIALS AND METHODS: Twenty-one patients with stage IA well-differentiated endometrial adenocarcinoma were enrolled in a prospective study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Megestrol Acetate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396003.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


99. Signorelli M, Lissoni AA, Cormio G, Katsaros D, Pellegrino A, Selvaggi L, Ghezzi F, Scambia G, Zola P, Grassi R, Milani R, Giannice R, Caspani G, Mangioni C, Floriani I, Rulli E, Fossati R: Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol; 2009 Dec;16(12):3431-41
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study.
  • BACKGROUND: Five percent to 20% of stage I endometrial cancer patients undergoing total abdominal hysterectomy and bilateral salpingo-oophorectomy develop vaginal and pelvic recurrences.
  • This randomized trial aimed to determine whether a modified radical (Piver-Rutledge class II) hysterectomy can improve survival and locoregional control compared to the standard extrafascial (Piver-Rutledge class I) hysterectomy.
  • METHODS: Eligible patients (n = 520) with stage I endometrial cancer were randomized to class I or class II hysterectomy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / surgery. Carcinoma, Adenosquamous / surgery. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834767.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


100. Brustmann H: Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia. Int J Gynecol Pathol; 2005 Apr;24(2):184-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia.
  • This study evaluated the immunohistochemical expression of human telomerase reverse transcriptase (hTERT) in endometrial carcinoma and atypical endometrial hyperplasia, and related it to the expression of topoisomerase (TP)IIalpha (a proliferation associated enzyme); apoptosis as determined by the frequency of apoptotic bodies (ABI); mitotic counts; and other clinicopathologic variables.
  • Immunoreactivity for hTERT and TPIIalpha as well as ABI were assessed in 57 endometrial samples (12 atypical hyperplasias, 33 endometrioid carcinomas, 12 serous/clear cell carcinomas).
  • hTERT expression increased with ABI (p < 0.0001), TPIIalpha LI (p = 0.0019), ABI/TPIIalpha ratios (p < 0.0001), and grade (p = 0.0005), but not with FIGO stage (p = 0.2775).
  • TPIIalpha LI, ABI, and ratios were related to high grade (p = 0.0001 for each variable), but not with FIGO stage (p = 0.7362, p = 0.7554, and p = 0.7405, respectively).
  • These results suggest that hTERT expression is closely related to proliferation, apoptosis, and high grade in endometrial carcinomas, reflecting cell cycle deregulation in endometrial carcinogenesis.
  • [MeSH-major] Adenocarcinoma / enzymology. Antigens, Neoplasm / biosynthesis. Apoptosis / physiology. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Endometrial Hyperplasia / enzymology. Endometrial Neoplasms / enzymology. Telomerase / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782075.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down






Advertisement